This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use:

This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated.
A copy can be downloaded for personal non-commercial research or study, without prior permission or charge.
This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author.
The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author.
When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given.
APPENDIX

A.1. DIAMOND Trial Protocol

A.2. DIAMOND Patient Information Sheet – Consent Form

A.3. DIAMOND Scotland A Research Ethics Committee Approval

A.4. DIAMOND Administration of Radioactive Substances Approval

A.5. DIAMOND NHS Lothian Research and Development Approval

A.6. DIAMOND Sponsors Authorisation to Recruit

A.7. DIAMOND Sponsors Authorisation to Dose

A.8. DIAMOND Lab Certificate
A.1 DIAMOND Trial Protocol

Dual antiplatelet therapy to inhibit coronary Atherosclerosis and Myocardial injury in patients with Necrotic high-risk coronary plaque Disease

<table>
<thead>
<tr>
<th>Co-sponsors</th>
<th>University of Edinburgh &amp; NHS Lothian ACCORD The Queen’s Medical Research Institute 47 Little France Crescent Edinburgh EH16 4TJ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funder</td>
<td>Wellcome Trust and AstraZeneca</td>
</tr>
<tr>
<td>Funding Reference Number</td>
<td>WT103782AIA - Senior Investigator Award</td>
</tr>
<tr>
<td>AstraZeneca Reference Number</td>
<td>ISSBRIL0250</td>
</tr>
<tr>
<td>Chief Investigator</td>
<td>Professor David Newby</td>
</tr>
<tr>
<td>EudraCT Number</td>
<td>2014-000952-26</td>
</tr>
<tr>
<td>REC Number</td>
<td>14/SS/0089</td>
</tr>
<tr>
<td>ClinicalTrials.gov ID number</td>
<td>NCT02110303</td>
</tr>
<tr>
<td>Version Number and Date</td>
<td>3.0, 10th March 2016</td>
</tr>
</tbody>
</table>
### COORDINATING CENTRE

<table>
<thead>
<tr>
<th>Chief Investigator</th>
<th>Co-sponsor Representative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor David E Newby</td>
<td>Fiach O'Mahony</td>
</tr>
<tr>
<td>Centre of Cardiovascular Science</td>
<td>University of Edinburgh</td>
</tr>
<tr>
<td>Chancellor's Building</td>
<td>Queen's Medical Research Institute</td>
</tr>
<tr>
<td>51 Little France Crescent</td>
<td>47 Little France Crescent</td>
</tr>
<tr>
<td>Edinburgh EH16 4SB</td>
<td>Edinburgh EH16 4TJ</td>
</tr>
<tr>
<td>Tel: 0131 242 6515</td>
<td>Tel: 0131 242 9418</td>
</tr>
<tr>
<td>Fax: 0131 242 6379</td>
<td>Email: <a href="mailto:fiach.o.mahony@ed.ac.uk">fiach.o.mahony@ed.ac.uk</a></td>
</tr>
<tr>
<td>Email: <a href="mailto:d.e.newby@ed.ac.uk">d.e.newby@ed.ac.uk</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Trial Statistician</th>
<th>PARTICIPATING SITES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steff Lewis</td>
<td>Edinburgh Royal Infirmary</td>
</tr>
<tr>
<td>Centre for Population Health Sciences</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>University of Edinburgh</td>
<td>Philip Adamson</td>
</tr>
<tr>
<td>Teviot Place</td>
<td>Centre of Cardiovascular Science</td>
</tr>
<tr>
<td>Edinburgh</td>
<td>Chancellor's Building</td>
</tr>
<tr>
<td>EHB 9AG</td>
<td>51 Little France Crescent</td>
</tr>
<tr>
<td>Tel: 0131 650 3198</td>
<td>Tel: 0745 345 8084</td>
</tr>
<tr>
<td>Email: <a href="mailto:steff.lewis@ed.ac.uk">steff.lewis@ed.ac.uk</a></td>
<td>Email: <a href="mailto:philadamson.nz@gmail.com">philadamson.nz@gmail.com</a></td>
</tr>
</tbody>
</table>
CONTENTS

1 INTRODUCTION ........................................................................................................... 9
  1.1 BACKGROUND ........................................................................................................ 9
  1.1.1 Pathogenesis of Coronary Artery Disease ....................................................... 9
  1.1.2 Ticagrelor ........................................................................................................... 9
  1.1.3 Non-invasive Imaging of the Vulnerable Plaque ............................................. 9
  1.1.4 High-Sensitivity Cardiac Troponin I ............................................................... 10
  1.2 Research Hypothesis ............................................................................................. 10
  1.3 RATIONALE FOR STUDY .................................................................................... 10

2 STUDY OBJECTIVES .................................................................................................. 11
  2.1 OBJECTIVES ........................................................................................................ 11
    2.1.1 Primary Objective .......................................................................................... 11
    2.1.2 Secondary Objectives ................................................................................... 11
    2.1.3 Safety Objective .......................................................................................... 11
    2.1.4 Exploratory Objectives ............................................................................... 11
  2.2 ENDPOINTS .......................................................................................................... 11
    2.2.1 Primary Endpoint ......................................................................................... 11
    2.2.2 Secondary Endpoints .................................................................................. 12

3 STUDY DESIGN .......................................................................................................... 12
  3.1 RATIONAL FOR STUDY DESIGN, DOSES AND CONTROL GROUPS ................. 12

4 STUDY POPULATION ................................................................................................ 12
  4.1 NUMBER OF PARTICIPANTS ............................................................................... 12
  4.2 INCLUSION CRITERIA ........................................................................................... 12
  4.3 EXCLUSION CRITERIA ......................................................................................... 13
  4.4 CO-ENROLMENT .................................................................................................. 13

5 PARTICIPANT SELECTION AND ENROLMENT ........................................................... 14
  5.1 IDENTIFYING PARTICIPANTS ............................................................................ 14
  5.2 CONSENTING PARTICIPANTS .......................................................................... 14
  5.3 SCREENING FOR ELIGIBILITY ......................................................................... 14
  5.4 INELIGIBLE AND NON-RECRUITED PARTICIPANTS ........................................... 14
  5.5 PROCEDURES FOR HANDLING SUBJECTS INCORRECTLY ENROLLED, RANDOMISED OR INITIATED ON INVESTIGATIONAL MEDICINAL PRODUCT ........................................................................................................ 14
  5.6 RANDOMISATION ................................................................................................ 14
    5.6.1 Randomisation Procedures ......................................................................... 14
    5.6.2 Treatment Allocation .................................................................................. 15
    5.6.3 Methods to Ensure Blinding ........................................................................ 15

CR007-T01v2.1
Page 3 of 39
PROTOCOL APPROVAL

DIAMOND
EUdraCT number 2014-000952-26

Signatures

Professor David Newby
Chief Investigator
Signature
Date

Steff Lewis
Trial Statistician
Signature
Date

Fiach O’Mahony
Sponsor(s) Representative
Signature
Date

Philip Adamson
Principal Investigator
Signature
Date
### LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCORD</td>
<td>Academic and Clinical Central Office for Research &amp; Development - Joint office for University of Edinburgh and NHS Lothian</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>AR</td>
<td>Adverse Reaction</td>
</tr>
<tr>
<td>CI</td>
<td>Chief Investigator</td>
</tr>
<tr>
<td>CT</td>
<td>Computer Tomography</td>
</tr>
<tr>
<td>CTA</td>
<td>Clinical Trial Authorisation</td>
</tr>
<tr>
<td>CTCa</td>
<td>Computer Tomography Coronary Angiography</td>
</tr>
<tr>
<td>CTIMP</td>
<td>Clinical Trial of an Investigational Medicinal Product</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribosine Nucleic Acid</td>
</tr>
<tr>
<td>eGFR</td>
<td>Estimated Glomerular Filtration Rate</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>IMP</td>
<td>Investigational Medicinal Product</td>
</tr>
<tr>
<td>ISF</td>
<td>Investigator Site File</td>
</tr>
<tr>
<td>MHRA</td>
<td>Medicines and Healthcare products Regulatory Authority</td>
</tr>
<tr>
<td>NIMP</td>
<td>Non Investigational Medicinal Product</td>
</tr>
<tr>
<td>PET</td>
<td>Positron Emission Tomography</td>
</tr>
<tr>
<td>PLATO</td>
<td>PLATElet Inhibition and Patient Outcomes</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>Research &amp; Development</td>
</tr>
<tr>
<td>REC</td>
<td>Research Ethics Committee</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>SAR</td>
<td>Serious Adverse Reaction</td>
</tr>
<tr>
<td>SmPC</td>
<td>Summary of Product Characteristics</td>
</tr>
<tr>
<td>SOP</td>
<td>Standard Operating Procedure</td>
</tr>
<tr>
<td>SUSAR</td>
<td>Suspected Unexpected Serious Adverse Reaction</td>
</tr>
<tr>
<td>TMF</td>
<td>Trial Master File</td>
</tr>
<tr>
<td>UAR</td>
<td>Unexpected Adverse Reaction</td>
</tr>
</tbody>
</table>
1 INTRODUCTION

1.1 BACKGROUND

1.1.1 Pathogenesis of Coronary Artery Disease

Coronary plaque rupture of mildly stenotic coronary atherosclerosis is the commonest cause of acute coronary thrombosis and myocardial infarction [Davies, 2000]. This is the dominant type of plaque event causing an acute coronary syndrome, especially in men. It is closely linked to hypercholesterolaemia and has a dominant inflammatory phenotype. Classical histological features include a lipid-rich pool, thin fibrous cap, paucity of vascular smooth muscle cells and an intense inflammatory cell infiltrate [Davies, 2000].

Plaque rupture does not invariably lead to thrombotic occlusion of the coronary artery. Coronary plaque events are very common and the majority of such events do not cause coronary occlusion [Mann & Davies, 1999; Davies, 2000]. Here, plaque rupture and thrombosis is organised, remodelled and incorporated into the atherosclerotic plaque itself. Indeed, 80% of plaques that cause over 50% diameter stenosis have evidence of old healed plaque rupture with incorporation of thrombus into the atheroma [Mann & Davies, 1999]. This process contributes to the progression of coronary atherosclerosis and explains the first appearance, or step change in severity, of angina pectoris.

Coronary plaque events are often not isolated. Plaque rupture can occur throughout the body and is not confined to a single vascular bed. Moreover, in patients with acute coronary syndromes, it is common for multiple plaque events to occur simultaneously and beyond the culprit lesion itself. Post-mortem studies indicate that, on average, 2.4 coronary thrombotic events occur in each patient who presents with fatal coronary heart disease [Mann & Davies, 1999; Davies, 2000]. This suggests that systemic and generalised mechanisms and mediators play an important role in addition to local factors within the coronary artery wall.

In summary, coronary atherosclerosis is characterised by multiple and recurrent plaque rupture events that are often sub-clinical and cause step-wise growth of the plaque as it heals and remodels. Patients undergoing repeated plaque rupture events are likely to be at increased risk of myocardial infarction, especially if such an event coincides with a period of increased blood thrombogenicity. If these patients can be identified then there would be a clear rationale for using powerful anti-platelet agents, such as ticagrelor, to dampen down their thrombotic potential and the risk of adverse cardiovascular events.

1.1.2 Ticagrelor

Ticagrelor (AZD6140) is a reversible and direct-acting oral antagonist of the adenosine diphosphate P2Y12 receptor. It provides faster, greater, and more consistent P2Y12 inhibition than clopidogrel [Gurbel et al., 2009]. In the PLATElet inhibition and patient Outcomes (PLATO) trial of 18,624 patients presenting with an acute coronary syndrome, ticagrelor was superior to clopidogrel for the prevention of cardiovascular events and death [Wallentin et al., 2009]. It is unknown whether these anti-platelet and anti-thrombotic benefits extend to patients with coronary artery disease in the absence of an acute coronary syndrome.

1.1.3 Non-invasive Imaging of the Vulnerable Plaque

In the study of coronary artery disease, many researchers have searched for a non-invasive imaging biomarker of plaque vulnerability and rupture. For the first time, we have demonstrated that 18F-fluoride positron emission tomography can detect high-risk coronary plaque in patients with stable coronary artery disease [Joshi et al., 2013].

In the vasculature, 18F-fluoride acts as a marker of novel calcification activity [Dweck et al., 2012a; Dweck et al., 2013]. Similar to other conditions, calcification in coronary atheroma occurs as a healing response to intense necrotic inflammation, making 18F-fluoride a useful marker of high-risk atherosclerotic plaque. We have previously demonstrated increased uptake of this tracer in the coronary vasculature localizing to individual coronary lesions and identifying patients with increased cardiovascular risk factor profiles [Dweck et al., 2012b]. More recently
we have conducted a prospective study of 40 patients with myocardial infarction in whom 18F-fluoride localised to the culprit plaque (Figure 1) in over 90% of patients [Joshi et al, 2013]. This finding was confirmed in 12 patients with a recent stroke undergoing carotid endarterectomy where 18F-fluoride uptake was observed at the site of plaque rupture in 100% of patients and this uptake correlated with increased calcification activity and areas of necrosis on histology. Finally we studied 40 patients with stable coronary artery disease. Increased uptake was observed in 45% of these patients and this again localized to individual coronary plaques (Figure 2). Interestingly these lesions were associated with multiple high-risk markers on radiofrequency and gray-scale intravascular ultrasound (necrotic core, positive remodeling and microcalcification). Importantly, plasma high-sensitivity troponin concentrations were much higher in patients with 18F-fluoride positive plaques compared with patients without evidence of uptake (7.89±3.34 versus 3.10±1.69 ng/L, P=0.047; Figure 3). The latter observation is of particular interest as it supports the hypothesis that 18F-fluoride is detecting subclinical plaque rupture in those with stable disease, similar to its mechanism of activity following myocardial infarction. Moreover plasma troponin concentrations measured by a high-sensitivity assay also predict an adverse outcome amongst patients with stable coronary artery disease [Omland et al, 2013] and provide a useful surrogate biomarker of therapeutic efficacy.

1.1.4 High-Sensitivity Cardiac Troponin I

Cardiac troponins are regulatory muscle proteins that are released into the circulation following acute myocardial injury. Assays that quantify cardiac isoforms of troponin have greater specificity and sensitivity for the diagnosis of myocardial infarction than traditional cardiac enzymes. Indeed, we have demonstrated that this improved precision can lead to improved outcomes in patients with suspected acute coronary syndromes [Mills et al, 2011; Mills et al, 2012].

Recent advances have led to greatly improved assay sensitivity permitting quantification of extremely low concentrations of troponin with excellent precision. High-sensitivity cardiac troponin assays have limits of detection 10- to 100-fold lower than contemporary assays and are able to detect troponin in the circulation of the majority of healthy persons. Indeed, we have recently demonstrated important sex-specific thresholds for cardiac troponin when assessing patients with suspected acute coronary syndromes [Shah et al, 2013]. However, it is becoming increasingly recognized that plasma high-sensitivity troponin concentrations are powerful markers of future risk even when within the normal reference range. As previously indicated, plasma high-sensitivity troponin concentrations are increased in patients with high-risk 18F-fluoride positive coronary artery plaque [Joshi et al, 2013] and appear to predict an adverse outcome amongst patients with stable coronary artery disease [Omland et al, 2013].

1.2 RESEARCH HYPOTHESIS

Ticagrelor will reduce biomarkers of myocardial injury and inhibit disease progression in patients with stable coronary heart disease and evidence of high-risk coronary plaque defined by 18F-fluoride uptake on positron emission tomography.

1.3 RATIONALE FOR STUDY

The rationale for this study is based on two main observations relevant to the pathogenesis of coronary artery disease.

1. The majority of episodes of plaque rupture are subclinical because thrombus formation is non-occlusive and microembolism causes covert myocardial micro-injury that is insufficient to cause overt symptoms.

2. Cycles of rupture and non-occlusive thrombus formation lead to plaque expansion and coronary artery disease progression.

These two features can now be tracked using a high-sensitivity cardiac troponin I assay and computer tomography coronary angiography respectively.
Novel approaches to the diagnostic and prognostic assessment of coronary heart disease

Given this central role of thrombosis in atherogenesis, anti-thrombotic interventions have major potential to impact on the consequences and progression of atherosclerotic disease [Williams et al, 1997; Riuof et al, 2004; Kwon et al, 2005]. With the advent of more potent platelet inhibition with ticagrelor, there is now the opportunity to assess whether dual anti-platelet therapy can improve markers of myocardial injury and disease progression.

To enhance the opportunity to detect such effects, we propose a stratified medicine approach where we will specifically select patients who have evidence of high-risk or subclinical ruptured coronary artery plaque identified by coronary 18F-fluoride uptake. We will then compare outcomes between those with and those without uptake, anticipating that only patients with high-risk plaque will demonstrate evidence of reduced injury and disease progression.

2 STUDY OBJECTIVES

2.1 OBJECTIVES

2.1.1 Primary Objective
To determine whether ticagrelor will reduce plasma high-sensitivity troponin concentrations compared with placebo in patients with stable coronary heart disease and high-risk coronary atheroma.

2.1.2 Secondary Objectives
a) To assess whether ticagrelor will reduce plasma high-sensitivity troponin concentrations in patients without increased coronary 18F-fluoride uptake.

b) To assess whether ticagrelor will reduce plasma high-sensitivity troponin concentrations over a 1-year time frame.

c) To assess whether ticagrelor will reduce coronary plaque volume or calcium score at the site of 18F-fluoride uptake.

d) To confirm the reproducibility of 18F-fluoride PET positivity

e) To assess the natural history of 18F-fluoride PET positive coronary plaque

2.1.3 Safety Objective
To determine whether the addition of ticagrelor to standard optimal medical therapy is safe and well tolerated in patients with stable coronary heart disease on optimal medical therapy. All bleeding events will be categorised according to the previous PLATO criteria [Waltentin et al, 2009] and recorded on the CRF.

2.1.4 Exploratory Objectives
The study design will also allow us to establish the effect of ticagrelor on disease progression. Using the baseline and repeat computed tomography coronary angiograms, we will be able to investigate changes in plaque burden, calcium score and lesion severity alongside the end points described above. This will be assessed throughout the coronary circulation as well as specifically at the site of 18F-fluoride uptake. As a measurement of treatment compliance and efficacy, we will also assess platelet-monoocyte aggregates before and after in vitro stimulation with 20 μM adenosine diphosphate [Frelinger et al, 2011].

2.2 ENDPOINTS

2.2.1 Primary Endpoint
Plasma high sensitivity cardiac troponin I (hsTnI) concentration at 30 days in patients with coronary 18F-fluoride uptake.
2.2.2 Secondary Endpoints
   a) Plasma hsTnI concentrations at 30 days in patients without coronary 18F-fluoride uptake.
   b) High sensitivity cardiac troponin I (hsTnI) concentration at 30 days in total study population.
   c) Plasma hsTnI concentrations at 1 year
   d) Total calcium score at 1 year
   e) Plaque volume at 1 year at the site of baseline coronary 18F-fluoride uptake
   f) Reproducibility of 18F-fluoride uptake detected on PET imaging at 1 week
   g) Natural History of 18F-fluoride uptake over 1 year

3 STUDY DESIGN

3.1 RATIONALE FOR STUDY DESIGN, DOSES AND CONTROL GROUPS

The study will be a randomised double blind placebo-controlled trial to ensure a rigorous study design and the avoidance of systematic biases of outcome measures. All recruited patients will undergo computed tomography coronary angiography and 18F-fluoride positron emission tomography (PET) scanning at baseline. Patients will then be randomized to ticagrelor 90 mg or matched placebo twice daily [Wallentin et al, 2009]. The dose has been selected on the basis of the FLATO trial [Wallentin et al, 2009]. The control groups will be two-fold. First there will be the active and inactive comparators of ticagrelor and placebo. Second we will examine for the presence and magnitude of an effect in the groups of patients with or without coronary 18F-fluoride uptake. The primary outcome will be the comparison between ticagrelor and matched placebo on the change in plasma troponin concentration from baseline to one month in patients with coronary 18F-fluoride uptake. Secondary analyses will undertake the same assessment in patients without coronary 18F-fluoride uptake to determine whether this is particular to patients with high-risk coronary plaque or is seen in all patients with multivessel coronary artery disease.

Further longitudinal comparisons of these groups will determine whether the dominant effect on plasma troponin concentrations is seen only in the early phase or whether potential benefits are seen throughout the study period. Finally, we will assess whether in comparison to placebo, ticagrelor will inhibit progression of coronary atheroma (calcium score and plaque volume) at the site of high-risk coronary plaque.

An additional exploratory component to the study will be to assess the reproducibility and natural history of 18F-fluoride uptake within coronary plaques. This will be investigated with repeat PET scanning within a subgroup of the total population.

4 STUDY POPULATION

4.1 Number Of Participants

We will recruit 250 patients with stable coronary heart disease from the Edinburgh Heart Centre.

4.2 Inclusion Criteria

For inclusion in the study subjects should fulfill the following criteria:
1. Patients aged ≥40 years with angiographically proven multivessel coronary artery disease defined as at least two major epicardial vessels with any combination of either (a) >50% luminal stenosis, or (b) previous revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery).
2. Provision of informed consent prior to any study specific procedures
3. Receiving aspirin

4.3 Exclusion Criteria
Subjects should not enter the study if any of the following exclusion criteria are fulfilled:
1. An acute coronary syndrome within the last 12 months
2. An indication for dual anti-platelet therapy, such as drug eluting stent
3. Receiving thienopyridine therapy such as clopidogrel or prasugrel
4. Percutaneous coronary intervention or coronary artery bypass graft surgery within the last 3 months
5. Inability or unwilling to give informed consent
6. Women who are pregnant, breastfeeding or of child-bearing potential (women who have experienced menarche, are pre-menopausal and have not been sterilised) will not be enrolled into the trial
7. Known hypersensitivity to ticagrelor or one of its excipients
8. Active pathological bleeding or bleeding diathesis
9. Significant thrombocytopenia: platelets <100 x 10^9/L
10. History of intracranial haemorrhage
11. Moderate to severe liver impairment (Child’s Grade B or C)
12. Maintenance therapy with strong CYP3A4 inhibitors, such as ketoconazole, nefazodone, ritonavir, indinavir, atazanavir, or clarithromycin
13. Major intercurrent illness or life expectancy <1 year
14. Renal dysfunction (eGFR ≤30 mL/min/1.73 m²)
15. Contraindication to iodinated contrast agents
16. Planned coronary revascularization or major non-cardiac surgery in the next 12 months
17. Maintenance therapy with simvastatin or lovastatin at doses greater than 40mg daily
18. Receiving oral anticoagulants including warfarin, rivaroxaban, dabigatran or apixaban.

4.4 Co-Enrolment
Co-enrolment with another clinical trial of an investigational medical product or of a trial involving the use of an additional anticoagulant (e.g. warfarin, dabigatran, rivaroxaban or apixaban) or antiplatelet (e.g. clopidogrel, prasugrel) will not be allowed with this study. A minimum of 4 months must elapse between studies of this nature prior to patient being eligible.
Co-enrolment involving trials not excluded above will be allowed provided this is not expected to place undue burden upon participants and their families. Consideration will also be given to the total exposure to ionising radiation should additional studies require further exposure.
5 PARTICIPANT SELECTION AND ENROLMENT

5.1 IDENTIFYING PARTICIPANTS

Patients will be identified by their usual care team from outpatient clinics and existing clinical databases (the Tomcat and TrakCare databases). They will initially be approached (either verbally or in writing) for study recruitment by their usual care team who are based at the Edinburgh Heart Centre. Patients will be provided with a Patient Information Sheet and given an opportunity to ask questions about participation in the trial.

5.2 CONSENTING PARTICIPANTS

After 2 days, patients willing to participate in the trial will be asked to attend a consent and screening visit at the Clinical Research Facility, Edinburgh. Written informed consent will be obtained by a suitably qualified member of the research team before any study related procedures are performed. Patients will be advised to inform their physicians and dentists that they are enrolled on the study before any surgery is scheduled and before any new medicinal product is taken.

5.3 SCREENING FOR ELIGIBILITY

Screening of clinical records for eligibility will be performed after written consent is obtained. If eligibility cannot be confirmed based on pre-existing clinical investigations (i.e. standard clinical biochemical and haematological variables have not been assessed within the past 6 months) then blood tests will be obtained to assess these variables. Once a patient has agreed to participate and is deemed eligible they will be invited to attend the baseline visit.

Baseline assessments will include clinical history and examination, review of patient records to confirm study eligibility and record clinical profile, standard clinical biochemical and haematological variables, plasma high sensitivity cardiac troponin I measurement, 12-lead electrocardiogram, 18F-fluoride positron emission tomography, computed tomography coronary calcium score and angiography, and storage of plasma, serum and DNA for future analysis.

5.4 INELIGIBLE AND NON-RECRUITED PARTICIPANTS

Ineligible and non-recruited patients will receive standard medical care. An anonymised log will be kept of patients who were screened for the study and subsequently found to be ineligible or not recruited.

5.5 PROCEDURES FOR HANDLING SUBJECTS INCORRECTLY ENROLLED, RANDOMISED OR INITIATED ON INVESTIGATIONAL MEDICINAL PRODUCT

Patients incorrectly randomized to the wrong treatment group will be maintained on allocated therapy unless blinding has been compromised. Given that this is a mechanistic study and not a clinical endpoint trial, they will be assigned to the treatment they actually received as part of the statistical analysis. Records will be kept of the treatment they were originally assigned to, and the treatment they received.

After the first 30 and 90 patients have been randomized into the trial, ECTU will check to ensure that minimization has achieved matching of the two treatment groups.

5.6 RANDOMISATION

5.6.1 Randomisation Procedures

Eligible patients will be randomized using a web-based randomization service to ensure allocation concealment. Given the modest sample size, we will minimise treatment allocation
according to age, sex, baseline plasma troponin concentration and the presence of coronary 18F-fluorode uptake.

5.6.2 Treatment Allocation
The placebo and active medication will be presented in numbered packages in collaboration with the Investigational Supplies Group (University of Edinburgh).

5.6.3 Methods to Ensure Blinding
The inactive placebo comparator will be presented and packaged in a form that will be indistinguishable from the active medication, ticagrelor. Therefore the treating clinical staff and patient will be blind to the allocated treatment. An indication of treatment allocation will potentially be apparent with platelet-monocyte aggregate testing. This will be undertaken by a dedicated technician distinct from the clinical investigational team. Samples will be presented to the technician using anonymised sample codes. Results will be stored in the database but not released to the study investigators until the end of the trial.

5.6.4 Emergency Unblinding Procedures
Web-based computer randomisation software will generate a randomisation list based on the values used for minimisation. This list will then be provided to the Investigational Supplies Group (ISG) for drug labelling purposes. The randomisation software will also contain unblinding codes which can only be accessed using a username and password. A username and password will only be provided to the Sponsor and Pharmacy department and can be used if emergency unblinding is required. Requests for unblinding will either go through the Chief or Principal Investigator and unblinding will be performed as required by the study pharmacist.

5.6.5 Discontinuation of Investigational Medicinal Product
The investigational product will be discontinued under the following circumstances:

1. At the request of the patient or if the patient withdraws from the study.
2. By the investigator or the responsible clinician if this was felt to be in the best interests of the patient.
3. On completion of the study.

Brief interruptions of therapy will be permitted (<14 days) where there is a clinical need, such as unavoidable surgical intervention. In such circumstances, the IMP will be withdrawn 5 days prior to surgery and recommenced as appropriate by the clinical team.

5.6.6 Withdrawal of Study Participants
Participants are free to withdraw from the study at any point or a participant can be withdrawn by the investigator. If withdrawal occurs, the primary reason for withdrawal will be documented in the participant’s case record form. The patient will have the option of withdrawal from (i) the repeat PET and CT sub-study only (ii) study medication with continued study procedures and collection of clinical and safety data (iii) all aspects of the trial but continued use of data collected up to that point, (iv) all aspects of the trial with removal of all previously collected data.

Randomised patients who wish to be withdrawn from the study before they have provided a blood sample for the assessment of plasma troponin concentration at one month of the trial, will be withdrawn from the study and another participant will be recruited to replace them. Data on the original participant will be kept on the database.
Novel approaches to the diagnostic and prognostic assessment of coronary heart disease

6 INVESTIGATIONAL MEDICINAL PRODUCT AND PLACEBO

6.1 STUDY DRUG

<table>
<thead>
<tr>
<th>Investigational product</th>
<th>Dosage form and strength</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ticagrelor (AZD6410)</td>
<td>90 mg tablet</td>
<td>AstraZeneca</td>
</tr>
</tbody>
</table>

6.1.1 Study Drug Identification
Ticagrelor is presented as a round biconvex film-coated yellow tablet marked with Ø90˚ above ØET˚ on one side.

6.1.2 Study Drug Manufacturer
AstraZeneca AB
Gärtnavägen
SE-151 85 Södertälje
SWEDEN

6.1.3 Marketing Authorisation Holder
AstraZeneca AB
S-151 85
Södertälje
Sweden
MA number EU/1/10/655/001-006

6.1.4 Labelling and Packaging
AstraZeneca will supply study medication and placebo in prefilled HDPE bottles with Child resistant caps. The HDPE bottles will be clearly labelled for the purpose of this trial including the study title, trial subject number and study contact by the Investigational Supplies Group, Edinburgh (ISG).

A Qualified Person from ISG will then release the study drug to the Pharmacy Department at the Royal Infirmary of Edinburgh.

6.1.5 Storage
All study medication will be kept in a secure place under appropriate storage conditions in the Pharmacy Department at the Royal Infirmary of Edinburgh.

6.1.6 Summary of Product Characteristics or Investigators Brochure
The Summary of Product Characteristics (SmPC) is given in Appendix 1.

6.2 PLACEBO

AstraZeneca will supply a matched placebo in prefilled HDPE bottles with Child resistant caps. The placebo will then be labelled by ISG and released to the Pharmacy Department at the Royal Infirmary of Edinburgh.
6.3 **DOSSING REGIME**
One tablet twice daily for 12 months.

6.4 **DOSE CHANGES**
No alteration in the planned dosing regime will be allowed.

6.5 **PARTICIPANT COMPLIANCE AND ACCOUNTABILITY**
Members of the research team will assess treatment compliance at attendance of each of the study visits by interview and pill count. Non-compliance with the dosing regime will only be considered a protocol deviation if the participant takes less than 90% of the planned dose. Any unused study medication will be returned to the Pharmacy Department at the Royal Infirmary for destruction.

6.6 **OVERDOSE**
Ticagrelor is well tolerated in single doses up to 900 mg. Gastrointestinal toxicity was dose-limiting in a single ascending dose study. Other clinically meaningful adverse reactions which may occur with overdose include dyspnoea and ventricular pauses.

In the event of overdose, we will observe for these potential adverse reactions and consider ECG monitoring. There is currently no known antidote to reverse the effects of ticagrelor and it is not expected to be dialysable. Treatment of overdose will follow local standard medical practice. The expected effect of excessive ticagrelor dosing is prolonged bleeding risk associated with platelet inhibition. If bleeding occurs appropriate supportive measures will be taken.

If an overdose occurs in the course of the study, the investigators or other site personnel will inform appropriate AstraZeneca representatives within one day, i.e. immediately but no later than the end of the next business day of when he or she becomes aware of it.

The designated AstraZeneca representative will work with the investigator to ensure that all relevant information is provided to the AstraZeneca Patient Safety data entry site.

6.7 **OTHER MEDICATIONS**

6.7.1 **Non-Investigational Medicinal Products**
18F-Sodium Fluoride (18F-NaF)

At the time of positron emission tomography and computed tomography coronary angiography, patients may receive oral and/or intravenous beta-blockade, such as metoprolol 5-100 mg, to slow the heart rate to below 65 beats per minute to maximise image quality and reduce radiation exposure. Glyceryl trinitrate spray or tablet will be administered sublingually (200-400 μg) to induce coronary vasodilatation to enhance image quality of the coronary angiogram.

6.7.2 **Permitted Medications**
All patients will be maintained on aspirin 75 mg once daily and maximally tolerated dose of statin. Patients will be encouraged to be maintained on maximally tolerated doses of angiotensin-converting enzyme inhibition and beta-blocker therapy as clinically indicated and in accordance with local guidelines. Following completion of the study, the trial medications will be discontinued.

6.7.3 **Prohibited Medications**
- Strong CYP3A4 inhibitors, such as ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir. Thienopyridines such as prasugrel, clopidogrel and ticlopidine
7 STUDY ASSESSMENTS
Trial participants will undergo 8 study visits: screening visit, baseline, randomisation and after 1, 3, 6, 9 and 12 months.

7.1 SAFETY ASSESSMENTS
The study does not have any pre-specified safety outcome measures. However, all bleeding events will be categorized according to the previous PLATO criteria [Wallentin et al. 2009]. These will be reported through adverse event reporting mechanisms (see Section 10).

7.2 STUDY ASSESSMENTS
This is a prospective single-centre randomized double blind matched placebo controlled trial of ticagrelor 90 mg twice daily in patients with stable coronary artery disease for 1 year. Subjects will attend for clinical assessments at 30 days, 3, 6, 9 and 12 months with a final computed tomography coronary angiogram at the end of the study. The randomisation visit must be conducted within 25 days of the baseline visit.
### Novel approaches to the diagnostic and prognostic assessment of coronary heart disease

#### DIAMOND

**Version 3.0, 10th Mar 2016**

<table>
<thead>
<tr>
<th></th>
<th>Screening</th>
<th>Baseline</th>
<th>Randomisation</th>
<th>30 days</th>
<th>6 months</th>
<th>9 months</th>
<th>1 year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(&lt;10 days)</td>
<td>(Day 0)</td>
<td>(±10 days)</td>
<td>(±14 days)</td>
<td>(±14 days)</td>
<td>(±14 days)</td>
<td></td>
</tr>
<tr>
<td>Eligibility Criteria and PRB</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Continuing eligibility confirmed</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Concomitant medications</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Clinical History</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Physical Examination</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Clinical Biochemistry and haematology</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Blood sampling for hsTnT</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Blood sampling for PMA</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>12-lead ECG</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>A/E/SAE Reporting</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Treatment allocation/Medication dispensed</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Compliance check</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>18F-Fluoride PET</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

*Additional 18F-Fluoride PET scans will be performed in a subgroup only.*

- CT attenuation correction
- CT Calcium Score
- CT Coronary Angiogram

*Where it is not possible for the CT scan at the 1 year visit to be performed at the same time as the other 1 year study assessments participants may be asked to attend an additional visit during which the CT scan will be performed. In this situation the remainder of the study assessments will be performed within the planned visit window (± 14 days) and the CT scan will be arranged for the earliest practicable opportunity.*

#### 7.2.1 Baseline Assessments

Baseline assessments will include clinical history and examination, review of patient records to confirm study eligibility and record clinical profile, standard clinical biochemical and haematological variables, plasma high sensitivity cardiac troponin I measurement, platelet-monocyte aggregates, 12-lead electrocardiogram, 18F-fluoride positron emission tomography.
computed tomography coronary calcium score and angiography, and storage of plasma, serum and DNA for future analysis.

### 7.2.2 Follow Up Assessments

At 1, 3, 6, 9 and 12 months, participants will undergo repeat clinical assessment, blood sampling, and 12-lead electrocardiogram. Compliance will be recorded by patient history and tablet count by a delegated member of the research team. At the final study visit (12 months), subjects will also undergo a repeat computed tomography coronary calcium score and angiography.

Where it is not possible for the CT scan at the 12 month visit to be performed at the same time as the other 12 month study assessments participants may be asked to attend an additional visit during which the CT scan will be performed. In this situation the remainder of the study assessments will be performed within the planned visit window (± 14 days) and the CT scan will be arranged for the earliest practicable opportunity.

### 7.2.3 High Sensitivity Cardiac Troponin I

Plasma cardiac troponin I concentrations will be measured by the accredited Clinical Biochemistry Department of the Royal Infirmary of Edinburgh using the ARCHITECT hsTnI high-sensitive troponin I assay (Abbott Laboratories, Abbott Park, IL). This is the first commercially available high-sensitivity troponin I assay that has greater precision at very low concentrations compared with the contemporary assay. The limit of detection is 1.2 ng/L and the inter-assay coefficient of variation <10% at 4.7 ng/L. The upper reference limit (99th percentile) based on 4,590 samples from healthy men and women is 34 ng/L for men and 16 ng/L for women.

### 7.2.4 Positron Emission and Computed Tomography Coronary Angiography

Study scans will be performed in the Clinical Research Imaging Centre.

Patients with a heart rate exceeding 65 beats/min may receive intravenous or oral beta-blockade (e.g. 5 to 100 mg metoprolol) 1 h before computed tomography. All patients will receive sublingual glyceryl trinitrate (200-400 µg) just prior to the computed tomography coronary angiography.

All patients will undergo dual cardiac and respiratory-gated positron emission and computed tomography imaging of the coronary arteries with a hybrid scanner (64-multidetector Biograph mCT, Siemens Medical Systems, Erlangen, Germany). Study subjects will be administered a target dose of 250 MBq 18F-fluorode in a quiet environment for 60 min. An attenuation correction computed tomography scan (non-enhanced 120 kV and 50 mA) will then be performed, followed by positron emission tomography imaging of the thorax in list-mode for 30 min.

Computed tomography coronary calcium score and angiography will be undertaken in the same visit as the 18F-fluorode scan and again at 1 year. With the patient lying still on the scanner after acquisition of the positron emission tomography scan, an electrocardiogram-gated breath-hold computed tomography scan (non-contrast-enhanced, 40 mAs/rotation, 120 kV; CareDose, Siemens Medical Systems) of the coronary arteries will be performed at the following settings: 330 ms rotation time, 100 (body mass index [BMI] <25 kg/m²) or 120 (body mass index >25 kg/m²) kV tube voltage, 160-245 mAs tube current, 3.8 mm/rotation table feed, prospective (heart rate regular and <50/min), or retrospective (heart rate >60 /min) electrocardiogram-gated. Depending on the BMI, a bolus of 80-100 mL of contrast (400 mgI/mL, Imeron, Bracco, Milan, Italy) will be injected intravenously at 5 mL/s, after determining the appropriate trigger delay with a test bolus of 20 mL contrast material.

The positron emission tomography scans will be reconstructed in multiple phases of the cardiac cycle, with the diastolic phase (50-75%) used for analysis. The computed tomography coronary angiography scans will be reconstructed at 0.75 x 0.7 mm and 0.5 x 0.3 mm for retrospective and prospective acquisitions respectively at 60%, 65% and 70% of the cardiac cycle. Additional reconstructions will be undertaken as necessary. Positron emission tomography scans will correct for cardiac motion correction using electrocardiogram-gated images.

CR007-T01v2.1
Page 20 of 39
18F-F PET Natural History Sub-study

Using the same scan process as outlined above a sub-group of patients will be selected for 1 additional PET scan. In total this will involve 80 patients out of the total cohort. The first 20 participants to be scanned will be to assess the reproducibility of 18F-fluoride uptake and will undergo a second PET scan at the randomisation visit (1 week after the baseline scan). This group will comprise 10 patients from both of the PET positive and PET negative samples. Following this we will investigate the natural history of 18F-fluoride uptake by performing repeat PET scans on 60 patients in total from the initial PET positive sample with 20 patients scanned at the 3 month, 6 month and 12 month follow up visits. No individual patient will undergo more than 2 PET scans during the course of the study. In order to allow accurate co-registration of images, repeat CT coronary angiograms will be performed at the time of the repeat PET scans. The additional PET scan for those in the sub-study will be performed at the 1 week, 3 month, 6 month or 12 month visit but the additional CTCA scan will only be performed at 1 week, 3 month or 6 month visits as the CTCA scan at 12 months will be performed on all participants irrespective of whether they are taking part in the sub-study.

7.2.5 Platelet-Monocyte Aggregates

The effect of ticagrelor on platelet activation will be assessed before and after in vitro stimulation with 20μM adenosine diphosphate to assess inhibition of the P2Y12 receptor [Harding et al., 2007; Burdess et al., 2010; Frehling et al 2011]. This will be performed at the baseline visit (before study medication ingestion) and at the 30 day visit [Gurbel et al 2009; Frehling et al. 2011]. Platelet-monocyte aggregate measurements will be performed by a trained technician independent to the study team to ensure blinding of treatment allocation is not compromised.

Blood will be anticoagulated with D-phenylalanyl-L-prolyl-L-arginine chloromethylketone (PPACK; Cambridge Biosciences, UK). Five minutes after sample collection, samples will be stained with the following conjugated monoclonal antibodies: APC-conjugated CD14 (Becton-Dickinson, UK); PE-conjugated CD62P (Becton-Dickinson, UK); PE-Cy7-conjugated CD11b(Becton-Dickinson, UK); FITC-conjugated CD42a(Becton-Dickinson, UK); and 20μM adenosine diphosphate. Once stained, samples will be incubated for 20 min at room temperature and fixed with FACS-Lyse (PMA analysis) or paraformaldehyde (platelet analysis). Samples will be analyzed using a FACScalibur flow cytometer (Becton-Dickinson, USA). Platelet-monocyte aggregates will be defined as monocytes staining positive for CD42a, as described previously [Harding et al., 2007]. Analysis will be performed using FlowJo (TreeStar, USA).

7.2.6 Biological Samples

Blood samples will be collected and tested at baseline, 30 days and 3, 6, 9 and 12 months. At baseline, blood samples will be taken for routine clinical biochemistry and haematology (including full blood count, urea, creatinine and electrolytes, liver function tests, total cholesterol and glucose).

Approximately 20 mL of blood will be obtained on each visit except that an additional 20 mL will be taken at baseline for the clinical biochemistry and haematology assessments. Blood will also be stored for DNA extraction for subsequent analysis as appropriate.

Blood samples will be processed and stored in the Clinical Research Facility. Blood sample will be processed (plasma and serum) and stored at -80°C for later analysis of potential extracellular matrix and inflammatory biomarkers. Blood will also undergo DNA extraction and flow cytometric assessment for platelet monocyte aggregates [Burdess et al., 2010].

All samples will be stored in locked secure freezers and in compliance with the sponsor’s tissue governance policies. All samples will be retained unless consent is withdrawn by the participant who specifically requests that their samples are destroyed.
8 DATA COLLECTION

All trial data will be recorded onto written case record forms (CRF) by a member of the research team and then entered into electronic CRFs designed and developed by the Edinburgh Clinical Trials Unit.

9 STATISTICS AND DATA ANALYSIS

9.1 SAMPLE SIZE CALCULATION

Patients with increased 18F-fluoride activity had plasma high-sensitivity troponin concentrations that were more than double those patients without increased 18F-fluoride uptake (7.89±9.34 versus 3.10±1.89 ng/L; P=0.047) in our recent trial [Joshi et al, 2013]. Based upon the assumption that ticagrelor will reduce plasma high sensitivity troponin concentrations by one half (i.e. from 7.89 to 3.95 ng/L, with standard deviations of 9.34 and 1.89 respectively), we will require 48 patients per treatment arm at 80% power and two-sided P<0.05. Allowance for missing data brings this to 55 per group. We have previously demonstrated that 45% of patients with advanced but stable coronary artery disease demonstrate increased 18F-fluoride uptake so that in total we will need to recruit 250 patients with positron emission tomography to identify these 110 patients with coronary uptake of 18F-fluoride. The Edinburgh Heart Centre performs more than 5,000 diagnostic angiograms and 2,500 angioplasty procedures per year. This should allow an adequate pool of potentially suitable patients with angiographically proven stable coronary artery disease from which to recruit.

9.2 PROPOSED ANALYSES

9.2.1 Description of Analysis Sets

The primary analysis will be to determine whether ticagrelor will reduce plasma high-sensitivity troponin concentrations compared with placebo in patients with stable coronary heart disease and increased coronary 18F-fluoride uptake. For this primary analysis, we will exclude any patient who does not have a blood sample for estimation of the one-month plasma troponin concentration or whose compliance is deemed inadequate (as estimated from pill counts). The required level of medication compliance will be described in the statistical analysis plan.

9.2.2 Methods of Statistical Analysis

For the primary analysis, the change in plasma high-sensitivity troponin concentration from baseline to 30 days will be compared between the two treatment groups (ticagrelor and placebo) using linear regression, adjusting for the minimisation variables, in patients with coronary 18F-fluoride uptake. Prior to analysis, tests for normality will be undertaken and, where data are skewed, logarithmic transformation will be considered prior to analysis. Effect sizes and 95% confidence intervals will be calculated. Similar analyses will be performed for the assessment of troponin at 30 days in patients without coronary 18F-fluoride uptake, and in the study population as a whole; for troponin at 1 year; and for calcium score and plaque volume at 1 year at the site of baseline coronary 18F-fluoride uptake. Statistical analysis will be performed using SAS. A two-sided P<0.05 will be taken as statistically significant. A full statistical analysis plan will be documented prior to data base lock. This will be overseen by the trial statistician in the Edinburgh Clinical Trials Unit.

10 ADVERSE EVENTS

The Investigator is responsible for the detection and documentation of events meeting the criteria and definitions detailed below.
Full details of contraindications and side effects that have been reported following administration of the IMP can be found in the relevant Summary of Product Characteristics (SmPC).
Participants will be instructed to contact their Investigator at any time after consenting to join the trial if any symptoms develop. All adverse events (AE) that occur after joining the trial must be reported in detail in the Case Report Form (CRF) or AE form. In the case of an AE, the Investigator should initiate the appropriate treatment according to their medical judgment. After initially recording an AE, the Investigator should follow each AE until resolution of the event or until no longer medically indicated.

10.1 DEFINITIONS
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant which does not necessarily have a causal relationship with an investigational medicinal product (IMP).
An adverse reaction (AR) is any untoward and unintended response to an IMP which is related to any dose administered to that participant.
A serious adverse event (SAE), serious adverse reaction (SAR). Any AE or AR that at any dose:
- results in death of the clinical trial participant;
- is life threatening*;
- requires in-patient hospitalisation* or prolongation of existing hospitalisation;
- results in persistent or significant disability or incapacity;
- consists of a congenital anomaly or birth defect;
- results in any other significant medical event not meeting the criteria above.

*Life-threatening in the definition of an SAE or SAR refers to an event where the participant was at risk of death at the time of the event. It does not refer to an event which hypothetically might have caused death if it were more severe.

^Any hospitalisation that was planned prior to randomisation will not meet SAE criteria. Any hospitalisation that is planned post randomisation will meet the SAE criteria.

A suspected unexpected serious adverse reaction (SUSAR) is any AR that is classified as serious and is suspected to be caused by the IMP, that it is not consistent with the information about the IMP in the Summary of Product Characteristics (SmPC) or Investigators Brochure.

10.2 IDENTIFYING AEs AND SAEs
All AEs and SAEs will be recorded from the time a participant signs the consent form to take part in the study until the last study visit.
Participants will be asked about the occurrence of AEs/SAEs at every visit during the study. Open-ended and non-leading verbal questioning of the participant will be used to enquire about AE/SAE occurrence. Participants will also be asked if they have been admitted to hospital, had any accidents, used any new medicines or changed concomitant medication regimens. If there is any doubt as to whether a clinical observation is an AE, the event will be recorded.

CR007-T01v2.1
Page 23 of 39
AEs and SAEs may also be identified via information from support departments e.g. laboratories.

10.3 RECORDING AEs AND SAEs

When an AE/SAE occurs, it is the responsibility of the Investigator to review all documentation (e.g. hospital notes, laboratory and diagnostic reports) related to the event. The Investigator will then record all relevant information in the CRF and on the SAE form (if the AE meets the criteria of serious).

Information to be collected includes dose, type of event, onset date, Investigator assessment of severity and causality, date of resolution as well as treatment required, investigations needed and outcome.

10.4 ASSESSMENT OF AEs AND SAEs

Seriousness, causality, severity and expectedness will be assessed by the Principal Investigator. For randomised double blind studies, AEs will be assessed as though the participant is taking active IMP. Cases that are considered serious, possibly, probably or definitely related to IMP and unexpected (i.e. SUSARs) will be unblinded.

The Investigator is responsible for assessing each AE.

The Chief Investigator (CI) may not downgrade an event that has been assessed by an Investigator as an SAE or SUSAR, but can upgrade an AE to an SAE, SAR or SUSAR if appropriate.

10.4.1 Assessment of Seriousness

The Investigator will make an assessment of seriousness as defined in Section 10.1.

10.4.2 Assessment of Causality

The Investigator will make an assessment of whether the AE/SAE is likely to be related to the IMP according to the definitions below.

- **Unrelated**: where an event is not considered to be related to the IMP.
- **Possibly Related**: The nature of the event, the underlying medical condition, concomitant medication or temporal relationship make it possible that the AE has a causal relationship to the study drug. The assessment of causality will be made against the reference safety information found in the Summary of Product Characteristics.

Where non Investigational Medicinal Products (NIMPs) e.g. rescue/escape drugs are given: if the AE is considered to be related to an interaction between the IMP and the NIMP, or where the AE might be linked to either the IMP or the NIMP but cannot be clearly attributed to either one of these, the event will be considered as an AR. Alternative causes such as natural history of the underlying disease, other risk factors and the temporal relationship of the event to the treatment should be considered and investigated. The blind should not be broken for the purpose of making this assessment.

10.4.3 Assessment of Expectedness

If an event is judged to be an AR, the evaluation of expectedness will be made based on knowledge of the reaction and the relevant product information documented in the SmPC/IB.

The event may be classed as either:

- **Expected**: the AR is consistent with the toxicity of the IMP listed in the SmPC/IB.
- **Unexpected**: the AR is not consistent with the toxicity in the SmPC/IB.

10.4.4 Assessment of Severity
The Investigator will make an assessment of severity for each AE/SAE and record this on the CRF or SAE form according to one of the following categories:

Mild: an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with every day activities.

Moderate: an event that is sufficiently discomforting to interfere with normal everyday activities.

Severe: an event that prevents normal everyday activities.

Note: the term 'severe', used to describe the intensity, should not be confused with 'serious' which is a regulatory definition based on participant/event outcome or action criteria. For example, a headache may be severe but not serious, while a minor stroke is serious but may not be severe.

10.5 REPORTING OF SAEs/SARs/SUSARs

Once the Investigator becomes aware that an SAE has occurred in a study participant, the information will be reported to the ACCORD Research Governance & QA Office immediately or within 24 hours. If the Investigator does not have all information regarding an SAE, they should not wait for this additional information before notifying ACCORD. The SAE report form can be updated when the additional information is received.

The SAE report will provide an assessment of causality and expectedness at the time of the initial report to ACCORD according to Sections 10.4.2, Assessment of Causality and 10.4.3, Assessment of Expectedness.

The SAE form will be transmitted by fax to ACCORD on +44 (0)131 242 9447 or may be transmitted by hand to the office or submitted via email to Safety.Accord@ed.ac.uk. Only forms in a pdf format will be accepted by ACCORD via email.

Where missing information has not been sent to ACCORD after an initial report, ACCORD will contact the investigator and request the missing information.

All reports faxed to ACCORD and any follow up information will be retained by the Investigator in the Investigator Site File (ISF).

10.6 REGULATORY REPORTING REQUIREMENTS

The ACCORD Research Governance & QA Office is responsible for pharmacovigilance reporting on behalf of the co-sponsors (Edinburgh University and NHS Lothian).

The ACCORD Research Governance & QA Office has a legal responsibility to notify the regulatory competent authority and relevant ethics committee (Research Ethics Committee (REC) that approved the trial). Fatal or life threatening SUSARs will be reported no later than 7 calendar days and all other SUSARs will be reported no later than 15 calendar days after ACCORD is first aware of the reaction.

ACCORD will inform Investigators at participating sites of all SUSARs and any other arising safety information.

An Annual Safety Report/Development Safety Update Report will be submitted, by ACCORD, to the regulatory authorities and RECs listing all SARs and SUSARs.

10.7 ASTRA ZENECA REPORTING REQUIREMENTS

All SAEs will be reported to AstraZeneca within 7 days, whether or not considered causally related to the investigational product.

The report will indicate, either in the SAE report or the cover page, the causality of events in relation to all study medications and if the SAE is related to disease progression, as determined by the principal investigator.

A cover page/the SAE report will detail the following:
Novel approaches to the diagnostic and prognostic assessment of coronary heart disease

10.8 FOLLOW UP PROCEDURES

After recording and reporting an SAE, the Investigator will follow each participant until resolution or death of the participant. Follow up information on an SAE will be reported to the ACCORD office.

After initially recording an AE, the Investigator should follow each AE until resolution of the event or until no longer medically indicated.

11 PREGNANCY

Woman of child-bearing potential will not be enrolled into the trial (woman who have experienced menarche, are pre-menopausal, have not been sterilised or who are currently pregnant).

Pregnancy is not considered an AE or SAE; however, the Investigator will collect pregnancy information for any female participants or female partners of male participants who become pregnant while participating in the study. The Investigator will record the information on a Pregnancy Notification Form and submit this to the ACCORD office within 14 days of being made aware of the pregnancy.

All pregnant female participants and partners of male participants will be followed up until following the outcome of the pregnancy.

All outcomes of pregnancy will be reported to AstraZeneca.

12 TRIAL MANAGEMENT AND OVERSIGHT ARRANGEMENTS

12.1 TRIAL MANAGEMENT GROUP

The trial will be coordinated by a Project Management Group, consisting of the grant holders (Chief Investigator and Principal Investigator in Edinburgh) and a coordinating Clinical Research Facility nurse.

The Principal Investigator will oversee the study and will be accountable to the Chief Investigator. The Principal Investigator will be responsible for checking the CRFs for completeness, plausibility and consistency. Any queries will be resolved by the Investigator or delegated member of the trial team.

A Delegation Log will be prepared for each site, detailing the responsibilities of each member of staff working on the trial.
12.2 TRAIL STEERING COMMITTEE

A Trial Steering Committee (TSC) will be established to oversee the conduct and progress of the trial. The review of SAEs will be added to the TSC agenda to ensure that appropriate action is taken if any safety issues arise.

12.3 DATA MONITORING COMMITTEE

In the PLATelet inhibition and patient Outcomes (PLATO) trial of 18,624 patients presenting with an acute coronary syndrome, ticagrelor was superior to clopidogrel for the prevention of cardiovascular events and death [Wallentin et al, 2009]. There were modest increases in the risks of bleeding and low rates of other side effects, such as dyspnoea. It is extremely unlikely that we will observe any substantial increased risk in our trial population given the small sample size of 250 patients and the very similar disease population in the PLATO trial that had a 500-fold larger trial population size. For this reason, an independent Data Monitoring Committee (DMC) will not be convened for this study and all study adverse events will be reported to the sponsors and AstraZeneca and will be discussed by the TSC.

12.4 INSPECTION OF RECORDS

Investigators and institutions involved in the study will permit trial related monitoring and audits on behalf of the sponsor, REC review, and regulatory inspection(s). In the event of an audit or monitoring, the Investigator agrees to allow the representatives of the sponsor direct access to all study records and source documentation. In the event of regulatory inspection, the Investigator agrees to allow inspectors direct access to all study records and source documentation.

12.5 RISK ASSESSMENT

An independent risk assessment will be performed by an ACCORD Clinical Trials Monitor to determine if monitoring is required and if so, at what level. An independent risk assessment will also be carried out by the ACCORD Quality Assurance Group to determine if an audit should be performed before/during/after the study and if so, at what locations and at what frequency.

12.6 BENEFIT/RISK BALANCE

12.6.1 Benefits

Patients may benefit from the treatment intervention. The benefits of ticagrelor in addition to standard medical therapy may include a reduction in the consequences and progression of coronary artery disease. In the PLATO trial [Wallentin et al, 2009], there appeared to be an ongoing and continuous improvement in outcomes beyond three months of an acute coronary syndrome. Ticagrelor may therefore have important ongoing secondary preventative benefits even in patients with apparently stable coronary artery disease. This is the rationale for the ongoing trial of the prevention of cardiovascular events in patients with prior myocardial infarction using ticagrelor compared with placebo on a background of aspirin: the PEGASUS trial (NCT01225562).

Patients may also benefit from additional procedures and investigations that they will undergo as part of the study. This will include closer medical supervision and non-invasive imaging investigations that may identify important incidental findings.

12.6.2 Risks

The risks of ticagrelor principally relate to bleeding, transient bradycardia, and dyspnoea. As with most anti-thrombotic treatments, there is a risk of excess bleeding. The incidence of excess major bleeding was modest and we will ensure robust exclusion criteria to prevent inclusion of patients at risk of bleeding. Bradycardia have been described but are generally transient and do not require intervention. We will record 12-lead electrocardiograms at subject visits and question patients regarding symptoms of dizziness and syncope. For
Novel approaches to the diagnostic and prognostic assessment of coronary heart disease

Dyspnea, there is a 14% rate of breathlessness associated with ticagrelor in the PLATO trial [Wallerin et al, 2009]. However, again this is usually mild and self-limiting, and discontinuation of study medication was necessary in only 1% of patients.

There are some potential hazards of the non-invasive investigations that we will perform as part of the trial. The main issues relate to exposure to ionising radiation and contrast agent administration. We have a well-developed protocol for cardiac positron emission and computed tomography imaging that minimizes radiation exposure and has clear procedures for managing adverse contrast reactions. We anticipate that the total research protocol dose (TPRD) radiation exposure will be 30 mSv. The TPRD includes radiation exposure from both the PET and CT scans combined. The estimated associated risk of developing fatal cancer is proportional to dose. Using a risk of 5% per Sv (ARSAC Notes) in a healthy population in this age group the estimated associated risk of developing fatal cancer as a result of this exposure is in the region 1 in 50. This risk can be classified as moderate. It is likely that in a population of any patients in the age group 40-50 years the cancer risk is approximately 5% per Sv (and correspondingly less than 5% per Sv as age increases above 50 years). For comparison the average annual background radiation dose arising from natural sources of ionising radiation in the environment in the UK is 2.2 mSv. The TPRD of 30 mSv incurred in this study is approximately 13-14 times annual background radiation from natural sources. An objective of this study is to assess reproducibility of NaF PET/CT. A subgroup of 60 subjects will receive a second PET/CT and additional CT coronary angiogram. This increases the TPRD to 46 mSv in those subjects that have their repeat scan at the randomisation visit, 3 months or 6 months and to 38mSv in those that undergo their repeat scan at 12 months. The associated risk of developing cancer as a result of this exposure is in the region of 1 in 450. This risk can be classified as moderate. A TPRD of 46 mSv is approximately 21 times annual background radiation from natural sources in the UK. All subjects will have two CT coronary angiograms and those in the sub-studies returning at the randomisation visit, 3 months or 6 months will have 3 CT coronary angiograms. We note that in occasional individual cases the effective dose from CT coronary angiography may increase to approximately 20 mSv, if the subject’s heart rate cannot be kept sufficiently low, requiring an alternative retrospective gating technique to be used. This will add approximately 12 mSv to the total research protocol dose for all subjects having CTCA.

This can be compared with other commonly used cardiovascular imaging techniques, such as nucleotide myocardial perfusion imaging (15-20 mSv) and diagnostic coronary angiography (7 mSv) [Einstein et al, 2007]. The risks of exposure to the contrast medium include allergic reactions and impairment of kidney function. Amongst patients with moderate-to-severe chronic kidney disease, there is a 2-4% risk of kidney impairment after computed tomography angiography [Barrett et al, 2006]. The risk of contrast exposure in this study will be minimised by exclusion of high-risk patients who have significant kidney disease (estimated glomerular filtration rate <30 mL/min/1.73m²).

12.7 STUDY MONITORING AND AUDIT

An ACCORD Clinical Trials Monitor or an appointed monitor will visit the Investigator site prior to the start of the study and during the course of the study if required, in accordance with the monitoring plan if required. Risk assessment will determine if audit, by the ACCORD QA group, is required. Details will be captured in an audit plan. Audit of Investigator sites, study management activities and study collaborative units, facilities and 3rd parties may be performed.

13 GOOD CLINICAL PRACTICE

13.1 ETHICAL CONDUCT

The study will be conducted in accordance with the principles of the International Conference on Harmonisation Tripartite Guideline for Good Clinical Practice (ICH GCP).
A favorable ethical opinion will be obtained from the appropriate REC and local R&D approval will be obtained prior to commencement of the study.

13.2 REGULATORY COMPLIANCE
The study will not commence until a Clinical Trial Authorisation (CTA) is obtained from the appropriate Regulatory Authority. The protocol and study conduct will comply with the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended.

13.3 INVESTIGATOR RESPONSIBILITIES
The Investigator is responsible for the overall conduct of the study at the site and compliance with the protocol and any protocol amendments. In accordance with the principles of ICH GCP, the following areas listed in this section are also the responsibility of the Investigator. Responsibilities may be delegated to an appropriate member of study site staff.

13.3.1 Informed Consent
The Investigator is responsible for ensuring informed consent is obtained before any protocol specific procedures are carried out. The decision of a participant to participate in clinical research is voluntary and should be based on a clear understanding of what is involved.

Participants must receive adequate oral and written information – appropriate Participant Information and Informed Consent Forms will be provided. The oral explanation to the participant will be performed by the Investigator or qualified delegated person, and must cover all the elements specified in the Participant Information Sheet and Consent Form.

The participant must be given every opportunity to clarify any points they do not understand and, if necessary, ask for more information. The participant must be given sufficient time to consider the information provided. It should be emphasised that the participant may withdraw their consent to participate at any time without loss of benefits to which they otherwise would be entitled.

The participant will be informed and agree to their medical records being inspected by regulatory authorities and representatives of the sponsor(s) but understand that their name will not be disclosed outside the hospital.

The Investigator or delegated member of the trial team and the participant will sign and date the Informed Consent Form(s) to confirm that consent has been obtained. The participant will receive a copy of this document and a copy filed in the Investigator Site File (ISF) and participant’s medical notes.

13.3.2 Study Site Staff
The Investigator must be familiar with the IMP, protocol and the study requirements. It is the Investigator’s responsibility to ensure that all staff assisting with the study are adequately informed about the IMP, protocol and their trial related duties.

13.3.3 Data Recording
The Principle Investigator is responsible for the quality of the data recorded in the CRF at each Investigator Site. The source data plan identifies which source data correspond to CRF data and states which data are recorded directly into the CRF.

13.3.4 Investigator Documentation
Prior to beginning the study, each Investigator will be asked to provide particular essential documents to the ACCORD Research Governance & QA Office, including but not limited to:

- An original signed Investigator’s Declaration (as part of the Clinical Trial Agreement documents);
Novel approaches to the diagnostic and prognostic assessment of coronary heart disease

13.3.5 GCP Training
All study staff must hold evidence of appropriate GCP training.

13.3.6 Confidentiality
All laboratory specimens, evaluation forms, reports, and other records must be identified in a manner designed to maintain participant confidentiality. All records must be kept in a secure storage area with limited access. Clinical information will not be released without the written permission of the participant. The investigator and study site staff involved with this study may not disclose or use for any purpose other than performance of the study, any data, record, or other unpublished, confidential information disclosed to those individuals for the purpose of the study. Prior written agreement from the sponsor or its designee must be obtained for the disclosure of any said confidential information to other parties.

13.3.7 Data Protection
All Investigators and study site staff involved with this study must comply with the requirements of the Data Protection Act 1998 with regard to the collection, storage, processing and disclosure of personal information and will uphold the Act's core principles. Access to collated participant data will be restricted to those clinicians treating the participants, representatives of the sponsor(s) and representatives of regulatory authorities.

Computers used to collate the data will have limited access measures via user names and passwords.

Published results will not contain any personal data that could allow identification of individual participants.

14 STUDY CONDUCT RESPONSIBILITIES

14.1 PROTOCOL AMENDMENTS
Any changes in research activity, except those necessary to remove an apparent, immediate hazard to the participant in the case of a urgent safety measure, must be reviewed and approved by the Chief Investigator.

Amendments to the protocol must be submitted in writing to the appropriate REC, Regulatory Authority and local R&D for approval prior to participants being enrolled into an amended protocol.

14.2 PROTOCOL VIOLATIONS AND DEVIATIONS
Prospective protocol deviations, i.e. protocol waivers, will not be approved by the sponsors and therefore will not be implemented, except where necessary to eliminate an immediate hazard to study participants. If this necessitates a subsequent protocol amendment, this should be submitted to the REC, Regulatory Authority and local R&D for review and approval if appropriate.

Protocol deviations will be recorded in a protocol deviation log and logs will be submitted to the sponsors every 3 months. Each protocol violation will be reported to the sponsor within 3 days of becoming aware of the violation.
14.3 SERIOUS BREACH REQUIREMENTS

A serious breach is a breach which is likely to effect to a significant degree:

(a) the safety or physical or mental integrity of the participants of the trial; or

(b) the scientific value of the trial.

If a potential serious breach is identified by the Chief investigator, Principal investigator or delegate(s), the co-sponsors (accord.seriousbreach@ed.ac.uk) must be notified within 24 hours. It is the responsibility of the co-sponsors to assess the impact of the breach on the scientific value of the trial, to determine whether the incident constitutes a serious breach and report to regulatory authorities and research ethics committees as necessary.

14.4 STUDY RECORD RETENTION

All study documentation will be kept for a minimum of 5 years from the protocol defined end of study point. When the minimum retention period has elapsed, study documentation will not be destroyed without permission from the sponsor.

14.5 END OF STUDY

It is anticipated that the study will last 2 years: one year for recruitment and one year of follow-up. The end of study is defined as the last participant’s last visit.

The investigators and/or the trial steering committee and/or the co-sponsor(s) have the right at any time to terminate the study for clinical or administrative reasons.

The end of the study will be reported to the REC and Regulatory Authority within 90 days. or 15 days if the study is terminated prematurely. The investigators will inform participants of the premature study closure and ensure that the appropriate follow up is arranged for all participants involved.

A summary report of the study will be provided to the REC and Regulatory Authority within 1 year of the end of the study.

14.6 CONTINUATION OF DRUG FOLLOWING THE END OF STUDY

The study medication will not be continued at the trial conclusion as it is not currently licensed for use in stable coronary artery disease. Patients will remain eligible to use ticagrelor for any approved indication however (i.e. for 12 months following an acute coronary syndrome).

14.7 INSURANCE AND INDEMNITY

The co-sponsors are responsible for ensuring proper provision has been made for insurance or indemnity to cover their liability and the liability of the chief investigator and staff.

The following arrangements are in place to fulfill the co-sponsors’ responsibilities:

- The protocol has been designed by the Chief investigator and researchers employed by the University and collaborators. The University has insurance in place (which includes no-fault compensation) for negligent harm caused by poor protocol design by the Chief investigator and researchers employed by the University.

- Sites participating in the study will be liable for clinical negligence and other negligent harm to individuals taking part in the study and covered by the duty of care owed to them by the sites concerned. The co-sponsors require individual sites participating in the study to arrange for their own insurance or indemnity in respect of these liabilities.

- Sites which are part of the United Kingdom’s National Health Service will have the benefit of NHS Indemnity.
Novel approaches to the diagnostic and prognostic assessment of coronary heart disease

15 REPORTING, PUBLICATIONS AND NOTIFICATION OF RESULTS

15.1 AUTHORIZATION POLICY
Ownership of the data arising from this study resides with the study team. On completion of the study, the study data will be analysed and tabulated, and a clinical study report will be prepared in accordance with ICH guidelines.

15.2 PUBLICATION
The clinical study report will be used for publication and presentation at scientific meetings. Investigators have the right to publish orally or in writing the results of the study.
Summaries of results will also be made available to investigators for dissemination within their clinics (where appropriate and according to their discretion).

15.3 PEER REVIEW
The study protocol and outcomes data have been reviewed by AstraZeneca who have agreed to help support the conduct and part funding of this clinical trial. There is additional peer review from the Trial Steering Committee and the Edinburgh Clinical Trials Unit statistician as well as the Medical Research Council.

16 REFERENCES
ARSAC Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources -March 2006 (updated 2014) Appendix VII

CR007-T01v2.1
Page 32 of 39


Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S,

FIGURE 1 Focal 18f-Fluoride Uptake in Patients with Myocardial Infarction and Stable Angina

Patient with acute ST-segment elevation myocardial infarction with (A) proximal occlusion (red arrow) of the left anterior descending artery on invasive coronary angiography and (B) intense focal 18F-fluoride uptake (yellow-red) at the site of the culprit plaque (red arrow) on the combined positron emission and computed tomogram.

Patient with anterior non-ST-segment elevation myocardial infarction with (C) culprit (red arrow; left anterior descending artery) and bystander non-culprit (white arrow; circumflex artery) lesions on invasive coronary angiography that were both stented during the index admission. Only the culprit lesion had increased 18F-fluoride uptake on combined positron emission and computed tomography (D) following percutaneous coronary intervention.
FIGURE 2: Patients with Stable Angina and 18F-Fluoride Uptake

Representative examples for 18F-fluoride uptake in patients with stable angina. Panels A-D, computed tomography coronary angiograms; panels E-H, 18F-fluoride positron emission tomograms; and panels I-L, fused positron emission tomograms and computed tomography coronary angiograms.
FIGURE 3: High-Sensitivity Troponin I Levels in Patients With Stable Angina Who Have and Do Not Have Increased Coronary 18F-Fluoride Uptake
A.2 DIAMOND PATIENT INFORMATION SHEET – CONSENT FORM

Participant Information Sheet and Consent Form

Dual antiplatelet therapy to Inhibit coronary Atherosclerosis and MyOcardial injury in patients with Necrotic high-risk coronary plaque Disease – DIAMOND Study

You are being invited to take part in a research study. Before you decide whether or not to take part, it is important for you to understand why the research is being done and what it will involve. Please take time to read the following information carefully. Talk to others about the study if you wish. Contact us if there is anything that is not clear or if you would like more information. Take time to decide whether or not you wish to take part.

What is the purpose of the study?
This study will make use of a specialised heart scanning technique known as a Positron Emission Tomography (PET) scan. This type of scan is used to detect regions in the body that accumulate a particular type of molecule. A molecule known as 18F-Sodium Fluoride (18F-NaF) has recently been found to accumulate in inflamed regions of the wall of the heart arteries. This molecule is not produced by the body but can be manufactured and administered by injection and then detected by the PET scanner. It appears that this type of inflammation can frequently occur without causing symptoms but may be a sign of increased risk of experiencing a heart attack or developing chest pains (angina) in the future.

This study aims to use 18F-NaF PET scans to try to detect these regions of blood vessel inflammation and to determine if a particular blood thinning type of medication known as ticagrelor can help the artery heal. This medication has already been shown to be of significant benefit when given to patients who have recently experienced a heart attack but this study will determine if this benefit can be extended to patients with known heart disease but without a recent heart attack. In order to identify any benefit from this treatment we will be measuring the levels of a protein in the blood (cardiac troponin). We will be performing a follow-up CT scan of the arteries to see if the heart arteries have improved over the year of the study. Approximately one third of the participants who take part in the study will also be invited to take part in a sub-study where they will undergo repeat PET scanning to see how the amount and location of inflammation in the artery wall changes over time.

Why have I been asked to take part?
You have been asked to take part as you have been previously diagnosed with heart artery disease (hardening or narrowing of the heart arteries) and you may have previously undergone coronary stenting (angioplasty) or bypass surgery. We intend to recruit 250 patients with heart disease who have not experienced a heart attack within the past 12 months.

Do I have to take part?
No, it is up to you to decide whether or not to take part. If you do decide to take part you will be given this information sheet to keep and will be asked to sign a consent form. If you decide to take part you are still free to withdraw at any time and without giving a reason. Deciding not to take part or withdrawing from the study will not affect the healthcare that you receive, or your legal rights.
What will happen if I take part?
If you agree to take part in the study you will be invited to attend the Clinical Research Facility at Edinburgh Royal Infirmary where we will discuss the study and make sure you understand everything. You will then be asked to sign a consent form. You may need to have blood tests taken at this visit to confirm your eligibility for the study.

If you are eligible to take part in the study you will be asked to attend a total of 7 additional visits over 12 months. At each of these visits 20 ml of blood (about 1 tablespoon) will be collected except for the first visit where 40 mL (about 2 tablespoons) will be collected). The blood samples will be taken to perform a variety of routine and specialised tests. The samples will be stored in a secure manner with anonymised coding to ensure your personal information is protected. You have the right to ask for your blood samples to be destroyed at any time by contacting your study doctor. Some of your blood will be stored and used for genetic research (DNA testing) and in future ethically approved studies. If you do not wish for your samples to be used in genetic research or future research you may still take part in the main study.

At your first visit we will review your medical history and perform a brief physical examination. An electrocardiogram (ECG or heart tracing) will be recorded. You will then be asked to undergo a combined CT scan and PET scan of your heart. These scans will be performed at the Clinical Research Imaging Centre (University building adjacent to the Royal Infirmary of Edinburgh). In order to aid the quality of these scans you will be asked to refrain from alcohol and caffeine from midnight on the day of your appointment. The CT scan will require the use of contrast ‘dye’ which is administered via an injection. You will likely have received this ‘dye’ prior to involvement in this study during coronary angiograms. In addition we may give you a beta-blocker (for example metoprolol tablets or injection) to slow your heart rate and you will receive a spray of glyceryl trinitrate (GTN) under your tongue (this spray is commonly used by patients with angina). The PET scan will require the use of an intravenous injection of the 18F-NaF tracer molecule. During the scans you will lie on a flat scanning table and be asked at several stages to briefly hold your breath whilst the images are obtained.

You will be asked to return to the clinic and you will be randomly allocated, like the flip of a coin, to receive either ticagrelor (1x 90mg tablet twice a day) or placebo. This process is called ‘randomisation’ and you have equal chances of receiving either ticagrelor or placebo. A placebo is a dummy treatment; it will look like the medication but contains no active ingredients. Neither you nor the study investigators will know which type of tablet you have been assigned but records of this information will be retained by the NHS Lothian pharmacy department in case this needs to be revealed for any reason during the study.

Ticagrelor is given in addition to your usual medications including aspirin. It has been previously studied in a large study involving over 18,000 patients who had experienced a recent heart attack and has been shown to be generally well tolerated.

After this you will be asked to attend visits at 1, 3, 6 and 9 months where further blood samples and ECGs will be performed. We will also ask general questions about your health, other medications you may be taking and any possible side effects
from the treatment you are receiving. These visits will take approximately 30-45mins each.

The last visit will take place 12 months after you start the study and will be similar to the first visit in duration. You will undergo a CT scan at this appointment in addition to having blood samples taken and a heart tracing performed.

If you are invited to take part in the sub-study (you will be notified if this applies to during the study) you will undergo an additional PET and CT scan. The additional PET scans will be performed 1 week after the first scan or at 3, 6 or 12 months but the additional CT scan will only be performed at 1 week, 3 month or 6 months. You will not undergo more than 2 PET and 3 CT scans in total. You can choose whether you would like to take part in the sub-study. This decision will not impact on your participation in the main DIAMOND treatment trial.

During the study it is important that you notify your doctor or dentist that you are taking ticagrelor before any new surgery is scheduled or any new medication is taken.

**What are the possible benefits of taking part?**
You may benefit from the treatment intervention. The benefits of ticagrelor in addition to standard medical therapy may include better treatment of your heart arteries. You may also benefit from the additional procedures and investigations that you will undergo as part of the study. This will include closer medical supervision and non-invasive imaging investigations that may identify important incidental findings.

**What are the possible disadvantages and risks of taking part?**
It is not thought that there are many disadvantages; however, as with any medical procedure or medication there are small risks.

Ticagrelor is well tolerated by most patients but as with all medicines they are some potential side effects. The most common side effects are usually mild in nature and include an increased likelihood of bruising or nose bleeds. Other possible side effects include a slow heart rate or shortness of breath. Both these effects frequently resolve without stopping ticagrelor.

The most serious side effect relates to a small increased risk of serious bleeding (this increase is likely less than 1%). Because of this risk we will not include patients who have a history of serious bleeding disorders or who are taking other blood thinners (except aspirin) such as warfarin or clopidogrel.

PET scans and CT scans are routine medical procedures and are themselves associated with very few side effects. The most important potential side effect is the use of radiation and reaction to the contrast dye. We have a well-developed protocol for cardiac PET and CT imaging that minimizes radiation exposure and has clear procedures for managing contrast reactions. The amount of radiation used during the scans varies but we anticipate that the total extra radiation dose exposure will be 30 mSv spread across the trial period (up to 46 mSv for those included in the sub-study). This is the equivalent of around 13-14 years background exposure to radiation (up to 21 years background exposure for those included in the sub-study).

The estimated lifetime risk of developing cancer from an exposure of 30 mSv is approximately 1 in 650. Currently it is estimated that 450 out of every 1000 people
living in the UK will develop cancer at some stage during their lives. If you participate in this study, this risk may be increased to around 452 out of 1000 people.

There is also a very low risk of impairment of kidney function or developing an allergic reaction to the contrast dye used in the CT and PET scans. The risk of contrast exposure in this study will be minimised by excluding patients who have significant kidney disease or a history of allergic reactions to contrast dye.

**What if something abnormal is found in my scans or other tests?**
As part of this study we will obtain pictures of your chest, focusing on your heart. We expect to be able to see the heart arteries and whether there are any inflamed regions of the artery wall. After your scan, a specialist will examine these pictures (this will not be done on the day of your study). There is a small possibility that we will identify unexpected or unrelated changes in the heart or other chest organs. You should be aware that because our pictures are taken for a specific research purpose, not all abnormalities that might be detected by other CT or PET scans are necessarily seen. On rare occasions, we might find an abnormality that is significant and which should be investigated further. If we find such a significant abnormality, we will contact your GP in order to take things further. Although a significant abnormality is unlikely, you should be aware that if such an abnormality is detected and you are informed, then this may have consequences for your treatment.

In a similar manner we will be performing blood tests that may identify other unexpected abnormalities that could require additional follow-up or treatment. If this is the case we will notify your GP to organize this ongoing care.

Genetic samples will be analysed in an anonymised format and no information arising from these tests will be available to you or your GP.

**What if there is a problem?**
If you have a concern about any aspect of this study please contact Dr Adamson or Professor Newby who will do their best to answer your questions. The doctors can be contacted by telephoning the Royal Infirmary of Edinburgh (0131 242 1000) or using the contact details at the end of this information sheet.

In the unlikely event that something goes wrong and you are harmed during the research and this is due to someone’s negligence then you may have grounds for a legal action for compensation against NHS Lothian but you may have to pay your legal costs. The normal National Health Service complaints mechanisms will still be available to you (if appropriate).

**What happens when the study is finished?**
At the end of the research you will need to stop taking the ticagrelor or placebo tablets. Your blood and genetic samples will be retained in secure storage within the Clinical Research Facility for a period of not less than 5 years for the purposes of possible future analysis.

**Will my taking part in the study be kept confidential?**
All the information we collect during the course of the research will be kept confidential and there are strict laws which safeguard your privacy at every stage.

Study researchers will need access to your medical records to carry out this research. This data may be copied onto a secure storage facility in the University of
Edinburgh computer network to allow for analysis. This information will be password protected and accessible only by the study investigators.

With your consent we will inform your GP that you are taking part.
To ensure that the study is being run correctly, we will ask your consent for responsible representatives from the Sponsor, Regulatory Authorities and NHS Institution to access your medical records and data collected during the study, where it is relevant to you taking part in this research. The Sponsor is responsible for overall management of the study and providing insurance and indemnity.

All data will be stored with anonymised coding. This means that your name will be removed so that you cannot be identified.

What will happen to the results of the study?
The study will be written up as an academic research project and will be submitted for publication within a medical journal. It is likely that the results will also be presented at academic meetings or conferences. You will not be identifiable in any published results. If you would like a copy of the submitted journal article please contact Dr Adamson at the email address below.

Who is organising the research and why?
The study has been commissioned by the University of Edinburgh and NHS Lothian. The sponsor has been funded by the Wellcome Trust (medical charity) and AstraZeneca (the manufacturers of ticagrelor).

Who has reviewed the study?
The study has been reviewed by The Scotland A Research Ethics Committee, the Medicines Healthcare products Regulatory Agency (MHRA) and NHS Lothian Research & Development Department.

If you have any further questions about the study please contact Dr Philip Adamson on 0131 242 1000 (via Royal Infirmary of Edinburgh switchboard) or email: Philip.adamson@nhslothian.scot.nhs.uk

If you would like to discuss this study with someone independent of the study please contact:
Dr Nicholas Crudin, Consultant Cardiologist, Royal Infirmary of Edinburgh
Nick.Crudin@nhslothian.scot.nhs.uk

If you wish to make a complaint about the study please contact NHS Lothian:
NHS Lothian Complaints Team
2nd Floor
Waverley Gate
2 - 4 Waterloo Place
Edinburgh
EH1 3EG
Tel: 0131 465 5768
complaints.team@nhslothian.scot.nhs.uk.

Thank you for taking the time to read this information sheet.
CONSENT FORM

DIAMOND – Dual Antiplatelet Therapy to Reduce Myocardial Injury

Participant ID:

Please initial box

1. I confirm that I have read and understand the information sheet (as specified in this document header) for the above study and have had the opportunity to consider the information and ask questions.

2. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected.

3. I understand that relevant sections of my medical notes and data collected during the study may be looked at by individuals from the Sponsor, from the NHS organisation or Regulatory Authorities, where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records.

4. I agree to my General Practitioner being informed of my participation in this study.

5. I understand that the results of this study may be used for future commercial development of products/tests/treatments and I will not benefit financially from this.

6. I agree to give a blood sample that will be used for genetic (DNA) analysis. (optional – please initial either the Yes or No box).

7. I agree to my data/tissue being used for future ethically approved studies and my anonymised data/tissue being used in future studies. (optional – please initial either the Yes or No box).

8. I agree to undergo an additional PET and CT scan if selected for involvement in the sub-study. (optional – please initial either the Yes or No box).

9. I agree to take part in the above study.

Name of Participant 

Date 

Signature 

Name of Person taking consent 

Date 

Signature 

1x original – into Site File, 1x copy – to Participant, 1x copy – into medical records
A.3 DIAMOND SCOTLAND A RESEARCH ETHICS COMMITTEE APPROVAL

Scotland A Research Ethics Committee

Dr Philip D Adamson
Centre for Cardiovascular Science
Chancellor's Building
49 Little France Crescent
Edinburgh
EH16 4SA

Research Ethics Service
NHS SCOTLAND
2nd Floor Waverley Gate
2-4 Waterloo Place
Edinburgh
EH1 3RG
Telephone: 0131 465 5680
www.nres.nhs.uk

Date: 27 June 2014

Dear Dr Adamson

Study title: Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients with Necrotic High-risk Coronary Plaque Disease

REC reference: 14/SS/0089
EudraCT number: 2014-00952-26
IRAS project ID: 148432

Thank you for your letter responding to the Committee’s request for further information on the above research and submitting revised documentation.

The further information has been considered on behalf of the Committee by the Chair.

We plan to publish your research summary wording for the above study on the HRA website, together with your contact details. Publication will be no earlier than three months from the date of this opinion letter. Should you wish to provide a substitute contact point, require further information, or wish to make a request to postpone publication, please contact the REC Manager, Walter Hunter, Walter.Hunter@nhshlothian.scot.nhs.uk

Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation (as revised), subject to the conditions specified below.

Conditions of the favourable opinion
The favourable opinion is subject to the following conditions being met prior to the start of the study.

Management permission or approval must be obtained from each host organisation prior to the start of the study at the site concerned.

Management permission ("R&D approval") should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements.

Guidance on applying for NHS permission for research is available in the Integrated Research Application System or at http://www.rdforum.nhs.uk.

Chairman Dr Ian Zealley
Vice-Chairman Dr Colin Selby
Novel approaches to the diagnostic and prognostic assessment of coronary heart disease

Where a NHS organisation’s role in the study is limited to identifying and referring potential participants to research sites (“participant identification centre”), guidance should be sought from the R&D office on the information it requires to give permission for this activity. For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation. Sponsors are not required to notify the Committee of approvals from host organisations.

Registration of Clinical Trials
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered on a publically accessible database within 6 weeks of recruitment of the first participant (for medical device studies, within the timeline determined by the current registration and publication trees).

There is no requirement to separately notify the REC but you should do so at the earliest opportunity e.g. when submitting an amendment. We will audit the registration details as part of the annual progress reporting process.

To ensure transparency in research, we strongly recommend that all research is registered but for non clinical trials this is not currently mandatory.

If a sponsor wishes to contest the need for registration they should contact Catherine Blewett (catherineblewett@nhs.net). The HRA does not, however, expect exceptions to be made. Guidance on where to register is provided within IRAS.

Clinical trial authorisation must be obtained from the Medicines and Healthcare products Regulatory Agency (MHRA).

The sponsor is asked to provide the Committee with a copy of the notice from the MHRA, either confirming clinical trial authorisation or giving grounds for non-acceptance, as soon as this is available.

It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).

Ethical review of research sites

NHS sites

The favourable opinion applies to all NHS sites listed in the application, subject to management permission being obtained from the NHS/HSC R&D office prior to the start of the study (see “Conditions of the favourable opinion” below).

Non-NHS sites

The Committee has not yet completed any site-specific assessment (SSA) for the non-NHS research site(s) taking part in this study. The favourable opinion does not therefore apply to any
non-NHS site at present. We will write to you again as soon as an SSA application(s) has been reviewed. In the meantime no study procedures should be initiated at non-NHS sites.

Approved documents
The final list of documents reviewed and approved by the Committee is as follows:

<table>
<thead>
<tr>
<th>Document</th>
<th>Version</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>GP/consultant information sheets or letters</td>
<td>1.1</td>
<td>05 May 2014</td>
</tr>
<tr>
<td>IRAS Checklist XML [Checklist_24062014]</td>
<td></td>
<td>24 June 2014</td>
</tr>
<tr>
<td>Other [Investigator CV: Dr Adamson]</td>
<td></td>
<td>12 April 2014</td>
</tr>
<tr>
<td>Participant consent form [PIS-CF with tracked changes]</td>
<td>1.5</td>
<td>05 June 2014</td>
</tr>
<tr>
<td>Participant information sheet (PIS) [PIS with tacked changes]</td>
<td>1.5</td>
<td>05 June 2014</td>
</tr>
<tr>
<td>REC Application Form</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research protocol or project proposal [DIAMOND Protocol with tracked changes following REC opinion]</td>
<td>1.5</td>
<td>21 June 2014</td>
</tr>
<tr>
<td>Sample diary card/patient card [Patient Emergency Card]</td>
<td>1.0</td>
<td>05 June 2014</td>
</tr>
<tr>
<td>Summary CV for Chief Investigator (CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Professor Newby</td>
<td>29 October 2012</td>
</tr>
</tbody>
</table>

Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

After ethical review
Reporting requirements

The attached document “After ethical review – guidance for researchers” gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study

The HRA website also provides guidance on these topics, which is updated in the light of changes in reporting requirements or procedures.
Feedback

You are invited to give your view of the service that you have received from the National Research Ethics Service and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/

We are pleased to welcome researchers and R & D staff at our NRES committee members’ training days – see details at http://www.hra.nhs.uk/hra-training/

14/SS/0089 Please quote this number on all correspondence

With the Committee’s best wishes for the success of this project.

Yours sincerely

Dr Ian Zaalley
Committee Chairman
cc: Ms Marianne Laird

Email: Walter.Hunter@nhsllothian.scot.nhs.uk

Enclosures: “After ethical review – guidance for researchers”
 Novel approaches to the diagnostic and prognostic assessment of coronary heart disease

A. 4 DIAMOND ADMINISTRATION OF RADIOACTIVE SUBSTANCES APPROVAL

CERTIFICATE
FOR THE
ADMINISTRATION OF RADIOACTIVE MEDICINAL PRODUCTS
Certificate Reference Number RPC 577 / 3258 / 32109

It is hereby certified for the purposes of the Medicines (Administration of Radioactive Substances) Regulations 1978, amended by the Medicines (Administration of Radioactive Substances) Amendment Regulations 1995, that

Prof Edwin Jacques Rudolph van BEEK
Royal Infirmary of Edinburgh
51 Little France Crescent
Edinburgh
EH16 4SA

may administer until 08-Oct-2019 the radioactive medicinal products specified in the Schedule to this certificate for the purpose(s) there specified.

For The Secretary of State for Health

Health Protection
Toxicology and Radiation
Department of Health

09-October-2014
Novel approaches to the diagnostic and prognostic assessment of coronary heart disease

Prof Edwin Jacques Rudolph van BEEK
Royal Infirmary of Edinburgh
51 Little France Crescent
Edinburgh
EH16 4SA

Date of Certificate 09-October-2014

Schedule to Research Certificate Number RPC 577 / 3258 / 32109

Research Project
Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients with Necrotic High-risk Coronary Plaque Disease

<table>
<thead>
<tr>
<th>Serial</th>
<th>Nuclide</th>
<th>Chemical Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>9a31</td>
<td>18F</td>
<td>NaF</td>
</tr>
</tbody>
</table>

End of Certificate Schedule
Novel approaches to the diagnostic and prognostic assessment of coronary heart disease

A.5 DIAMOND NHS Lothian Research and Development Approval

Dear Dr Adamson,

Lothian R&D Project No: 2014/0313
Title of Research: Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients with Necrotic Highrisk Coronary Plaque Disease
REC No: 14/SSI/0089
CTA No: 29901/0001/001-0001 Eudract: 2014-000952-26
Participant Information Sheet: Consent Form:
Version 1.8 dated 22nd August 2014
Version 1.8 dated 22nd August 2014
Protocol: v2.0, 05.10.14

I am pleased to inform you that this study has been approved for NHS Lothian and you may proceed with your research, subject to the conditions below. This letter provides Site Specific approval for NHS Lothian.

Please note that ACCORD policy for GCP & SOP Training requires you to have undertaken documented GCP training within the previous 24 months, before commencing activities with respect to the Project listed above. ACCORD policy also states that the Principal Investigator is responsible for ensuring that local research site staff members have undertaken GCP training before beginning Project specific activities.

According to EU directives, results data must be uploaded to the EudraCT public database after study closure. As study sponsor, the ACCORD office will upload data related to your study on your behalf. Once an end of trial notification is received by the ACCORD office, you will be contacted and the required data will be requested. Data for upload must be submitted to the ACCORD office within 10 months (4 months for paediatric studies) of your end of trial notification.

Please note that the NHS Lothian R&D Office must be informed if there are any changes to the study such as amendments to the protocol, recruitment, funding, personnel or resource input required of NHS Lothian.
Substantial amendments to the protocol will require approval from the ethics committee which approved your study and the MHRA where applicable.

Please inform this office when recruitment has closed and when the study has been completed.

I wish you every success with your study.

Yours sincerely

Fiona Mc Ardle
Deputy R&D Director

cc Professor David E Newby, Chief Investigator, RIE
    Dr Andrew Flapin, Associate Medical Director – Medicine Services RIE
    Ruairidh Buchan, Pharmacy, RIE
    Dawn Lyster, Labs, RIE
    Dr Duncan Martin, Business Manager, BRIC
    Dawn Cardy, Imaging Study Information Administrator, CRIC
    Fiona White, Study Information Manager, CRF
**A.6 DIAMOND SPONSORS AUTHORISATION TO RECRUIT**

![Sponsor's Authorisation to Open Trial Site](image)

<table>
<thead>
<tr>
<th>Study Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study name</td>
</tr>
<tr>
<td>REC reference</td>
</tr>
<tr>
<td>R&amp;D reference</td>
</tr>
<tr>
<td>Protocol version &amp; date</td>
</tr>
<tr>
<td>Study Site</td>
</tr>
<tr>
<td>PI name</td>
</tr>
</tbody>
</table>
| PI contact details     | Centre of Cardiovascular Science  
                        | Chancellor's Building  
                        | 51 Little France Crescent  
                        | Edinburgh  
                        | EH16 4SB  
                        | Phillip.adamson@ed.ac.uk |

<table>
<thead>
<tr>
<th>Monitor Actions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmed</td>
</tr>
<tr>
<td>Provide details to Clinical Research Administrator for SmPC tracker</td>
</tr>
<tr>
<td>Provide details to Clinical Research Administrator for APR/DSUR tracker</td>
</tr>
<tr>
<td>Inform CI of requirement to register trials on a publicly accessible database within 6 weeks of FPI due to HRA approval conditions (clinicaltrials.gov)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Verifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmed</td>
</tr>
<tr>
<td>REC favourable opinion provided and all conditions met</td>
</tr>
<tr>
<td>MHRA approval in place and all conditions met</td>
</tr>
<tr>
<td>R&amp;D management approval in place and all conditions met</td>
</tr>
</tbody>
</table>
## Sponsor's Authorisation to Open Trial Site

<table>
<thead>
<tr>
<th>Contractual conditions met</th>
<th>❑</th>
<th>❑</th>
<th>Double confirmed by Trial manager and ACCORD Research Governance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latest version/date of protocol signed by all signatories</td>
<td>❑</td>
<td>❑</td>
<td>Double confirmed by Trial manager and ACCORD Research Governance</td>
</tr>
<tr>
<td>Correct version/date of study documents present (PIS/Consent Form/adverts/etc)</td>
<td>❑</td>
<td>❑</td>
<td>Double confirmed by Trial manager and ACCORD Research Governance</td>
</tr>
<tr>
<td>PI CV in TMF and ISF</td>
<td>❑</td>
<td>❑</td>
<td>Double confirmed by Trial manager and ACCORD Research Governance</td>
</tr>
<tr>
<td>PI GCP evidence in TMF and ISF</td>
<td>❑</td>
<td>❑</td>
<td>Double confirmed by Trial manager and ACCORD Research Governance</td>
</tr>
<tr>
<td>Delegation Log in place</td>
<td>❑</td>
<td>❑</td>
<td>Completed at SIV</td>
</tr>
<tr>
<td>Screening Log in place</td>
<td>❑</td>
<td>❑</td>
<td>Double confirmed by Trial manager and ACCORD Research Governance</td>
</tr>
<tr>
<td>ID log to be used and in place</td>
<td>❑</td>
<td>❑</td>
<td>Double confirmed by Trial manager and ACCORD Research Governance</td>
</tr>
<tr>
<td>SIV process complete</td>
<td>❑</td>
<td>❑</td>
<td>Double confirmed by Trial manager and ACCORD Research Governance</td>
</tr>
<tr>
<td>Labels provided to labs for clinical trial samples</td>
<td>❑</td>
<td>❑</td>
<td>Double confirmed by Trial manager and ACCORD Research Governance</td>
</tr>
<tr>
<td>Combined Risk Assessment complete</td>
<td>❑</td>
<td>❑</td>
<td>Double confirmed by Trial manager and ACCORD Research Governance</td>
</tr>
<tr>
<td>Database checklist applied and study database acceptable</td>
<td>❑</td>
<td>❑</td>
<td>Database will not be used until signed off. QA will arrange sign off. Request to QA issued on 20150303.</td>
</tr>
<tr>
<td>Monitor access to database and eCRF in place</td>
<td>❑</td>
<td>❑</td>
<td>Trial manager will put this in place</td>
</tr>
<tr>
<td>Data capture detailed and approved by monitor</td>
<td>❑</td>
<td>❑</td>
<td>Approved for use by sponsor. Refer to pCRF tracker for detail of reviewers.</td>
</tr>
<tr>
<td>Agreement with investigator in TMF and ISF (site agreement or equivalent)</td>
<td>❑</td>
<td>❑</td>
<td>Double confirmed by Trial manager and ACCORD Research Governance</td>
</tr>
<tr>
<td>Adequate resources in place to begin recruitment</td>
<td>❑</td>
<td>❑</td>
<td>Double confirmed by Trial manager and ACCORD Research Governance</td>
</tr>
</tbody>
</table>

## CTIMP Study Verifications

<table>
<thead>
<tr>
<th>CTIMP Studies</th>
<th>Confirmed</th>
<th>Checked Remotely</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate facilities for product storage are confirmed (security, temperature)</td>
<td>❑</td>
<td>❑</td>
<td>Pharmacy visit to be conducted – trial does not have permissions to close yet</td>
</tr>
<tr>
<td>Arrangements for drug storage and accountability in place with pharmacy</td>
<td>❑</td>
<td>❑</td>
<td>Pharmacy visit to be conducted – trial does not have permissions to close yet</td>
</tr>
<tr>
<td>Drug labels accurate and consistent with MHRA approval</td>
<td>❑</td>
<td>❑</td>
<td>Pharmacy visit to be conducted – trial does not have permissions to close yet</td>
</tr>
<tr>
<td>Investigator's Brochure or SmPC in</td>
<td>❑</td>
<td>❑</td>
<td>Pharmacy visit to be conducted –</td>
</tr>
</tbody>
</table>
Novel approaches to the diagnostic and prognostic assessment of coronary heart disease

Sponsor’s Authorisation to Open Trial Site

<table>
<thead>
<tr>
<th>Place for all IMPs and NIMPs</th>
<th>Trial does not have permissions to dose yet</th>
<th>Pharmacy visit to be conducted – trial does not have permissions to dose yet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shipping records verified</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>COA/QP certification in place</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Pharmacy ready and approved to proceed</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>IMP in place</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Adequate resources in place to begin recruitment</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

Medical Device Study Verifications

<table>
<thead>
<tr>
<th>Medical Device Studies</th>
<th>Confirmed</th>
<th>Checked Remotely</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate facilities for product storage are confirmed (security, temperature)</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Arrangements for accountability in place</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Device labels accurate and consistent with MHRA approval</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Investigator’s Brochure in place</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Signed Manufacturer’s Authorisation in place</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Shipping records verified</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Adequate resources in place to begin recruitment</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
</tbody>
</table>

Authorised Documents

<table>
<thead>
<tr>
<th>Current</th>
<th>Document</th>
<th>Version</th>
<th>Author date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Protocol</td>
<td>2.1</td>
<td>01-Dec-14</td>
</tr>
<tr>
<td>Yes</td>
<td>PISC</td>
<td>2.2</td>
<td>19-Dec-14</td>
</tr>
<tr>
<td>Yes</td>
<td>Pt invite letter</td>
<td>1.1</td>
<td>29-Aug-14</td>
</tr>
<tr>
<td>Yes</td>
<td>GP letter</td>
<td>1.1</td>
<td>05-May-14</td>
</tr>
<tr>
<td>Yes</td>
<td>Pt emergency card</td>
<td>1.1</td>
<td>05-Jun-14</td>
</tr>
<tr>
<td>Yes</td>
<td>label</td>
<td>v0.3</td>
<td>20-Jun-14</td>
</tr>
<tr>
<td>Yes</td>
<td>SmPC AZ Brillique</td>
<td>N/A</td>
<td>25-Jun-14</td>
</tr>
</tbody>
</table>
**Sponsor's Authorisation to Open Trial Site**

<table>
<thead>
<tr>
<th>90mg</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>yes</td>
<td>ARSAC</td>
<td>N/A</td>
</tr>
<tr>
<td>yes</td>
<td>label</td>
<td>1</td>
</tr>
</tbody>
</table>

Confirmed as correct by trial manager on 20150302

**Declaration**

This document confers authorisation from the study sponsor to open the specified trial site for recruitment. This authorisation permits the research team to proceed with all study activities at the trial site.

**Signatures**

Authorisation Completion:

Sponsor authorisation confirmed by: Louisa Wilson  
Job Function: Senior Clinical Research Monitor  
Signature: [Signature]
Date: 03/03/2015

Authorisation Review

Not Required (authorised by SCTM)

Authorisation reviewed by:  
Job Function:  
Signature:  
Date: Click here to enter a date.
### A.7 DIAMOND SPONSORS AUTHORISATION TO DOSE

![Sponsor's Authorisation to Open Trial Site](image)

**Study Details**

<table>
<thead>
<tr>
<th>Study name</th>
<th>DIAMOND</th>
</tr>
</thead>
<tbody>
<tr>
<td>REC reference</td>
<td>14/55/0089</td>
</tr>
<tr>
<td>R&amp;D reference</td>
<td>2014/0313</td>
</tr>
<tr>
<td>Protocol version &amp; date</td>
<td>V2.1 (dated 01Dec2014)</td>
</tr>
<tr>
<td>Study Site</td>
<td>RIE CRF</td>
</tr>
<tr>
<td>PI name</td>
<td>Dr Phil Adamson</td>
</tr>
<tr>
<td>PI contact details</td>
<td>Centre of Cardiovascular Science, Chancellor's Building, 51 Little France Crescent, Edinburgh EH16 4SB, <a href="mailto:philip.adamson@ed.ac.uk">philip.adamson@ed.ac.uk</a></td>
</tr>
</tbody>
</table>

**Monitor Actions**

<table>
<thead>
<tr>
<th>Monitor Actions</th>
<th>Confirmed</th>
<th>Checked Remotely</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provide details to Clinical Research Administrator for SmPC tracker</td>
<td>☒</td>
<td>☐</td>
<td>Emailed Elizabeth Brownsell, ACCORD on 26Feb2015</td>
</tr>
<tr>
<td>Provide details to Clinical Research Administrator for APR/DSUR tracker</td>
<td>☒</td>
<td>☐</td>
<td>Emailed Elizabeth Brownsell, ACCORD on 26Feb2015</td>
</tr>
<tr>
<td>Inform CI of requirement to register trials on a publicly accessible database within 6 weeks of FPI due to HRA approval conditions (clinicaltrials.gov)</td>
<td>☒</td>
<td>☐</td>
<td>The trial is registered on clinicaltrials.gov and the number is on the front of the protocol</td>
</tr>
</tbody>
</table>

**Verifications**

<table>
<thead>
<tr>
<th>Confirmed</th>
<th>Checked Remotely</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>REC favourable opinion provided and all conditions met</td>
<td>☒</td>
<td>☐</td>
</tr>
<tr>
<td>MHRA approval in place and all conditions met</td>
<td>☒</td>
<td>☐</td>
</tr>
<tr>
<td>R&amp;D management approval in place and all conditions met</td>
<td>☒</td>
<td>☐</td>
</tr>
</tbody>
</table>
Novel approaches to the diagnostic and prognostic assessment of coronary heart disease

**Sponsor’s Authorisation to Open Trial Site**

<table>
<thead>
<tr>
<th>Condition</th>
<th>✔</th>
<th>☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contractual conditions met</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latest version/date of protocol signed by all signatories</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Correct version/date of study documents present (PIS/Consent Form/adverts/etc)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI CV in TMF and IF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI GCP evidence in TMF and ISF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delegation Log in place</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening Log in place</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ID log to be used and in place</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SIV process complete</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labels provided to labs for clinical trial samples</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined Risk Assessment complete</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Database checklist applied and study database acceptable</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

As per email from Elizabeth Brownsell on the 05Mar2015, the database checklist will not apply. In this communication, it was confirmed the decision of the Research Management Committee (RMC meeting on 00Mar2015) to not subject the ECTU database to review with the sponsor’s database checklist. The committee has agreed that ECTU are a well-known, experienced supplier of study databases with established and robust procedures.

<table>
<thead>
<tr>
<th>Condition</th>
<th>✔</th>
<th>☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monitor access to database and eCrf in place</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data capture detailed and approved by monitor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agreement with investigator in TMF and ISF (site agreement or equivalent)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adequate resources in place to begin recruitment</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**CTIMP Study Verifications**

- Not applicable – study is not a CTIMP

<table>
<thead>
<tr>
<th>CTIMP Studies</th>
<th>Confirmed</th>
<th>Checked</th>
<th>Notes</th>
</tr>
</thead>
</table>

CM001-T02 v1.0
Page 2 of 4
Novel approaches to the diagnostic and prognostic assessment of coronary heart disease

## Sponsor’s Authorisation to Open Trial Site

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Remotely</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate facilities for product storage are confirmed (security, temperature)</td>
<td>☒</td>
<td>As confirmed during a monitoring visit to the Pharmacy on the 17Mar2015.</td>
</tr>
<tr>
<td>Arrangements for drug storage and accountability in place with pharmacy</td>
<td>☒</td>
<td>As confirmed by the monitor during a visit to the Pharmacy on the 17Mar2015.</td>
</tr>
<tr>
<td>Drug labels accurate and consistent with MHRA approval</td>
<td>☒</td>
<td></td>
</tr>
<tr>
<td>Investigator’s Brochure or SmPC in place for all IMPs and NIMPs</td>
<td>☒</td>
<td>The monitor provided the correct version of the SmPC (dd 24Jul2014) immediately after finalised the monitoring visit on the 17Mar2015.</td>
</tr>
<tr>
<td>Shipping records verified</td>
<td>☒</td>
<td>The monitor noted that there was not temperature monitoring during the IMP shipment to the site. On the same day of this visit (17Mar2015), the IFG OQ confirmed that this control was deemed as unnecessary and that the stability of the IMP is not compromised.</td>
</tr>
<tr>
<td>CDA/QP certification in place</td>
<td>☒</td>
<td>Document fully signed on the 11Mar2015; valid for the blinded batch number 0035-01-001</td>
</tr>
<tr>
<td>Pharmacy ready and approved to proceed</td>
<td>☒</td>
<td>As confirmed by the monitor during a visit to the Pharmacy on the 17Mar2015.</td>
</tr>
<tr>
<td>IMP In place</td>
<td>☒</td>
<td>The Pharmacy received 702 bottles of the IMP, batch number 0035-01-001, as confirmed by the monitor during a visit to the Pharmacy on the 17Mar2015.</td>
</tr>
<tr>
<td>Adequate resources in place to begin recruitment</td>
<td>☒</td>
<td></td>
</tr>
</tbody>
</table>

## Medical Device Study Verifications

Not applicable – study is not of a medical device ☒

<table>
<thead>
<tr>
<th>Medical Device Studies</th>
<th>Confirmed</th>
<th>Checked Remotely</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate facilities for product storage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrangements for accountability in place</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Device labels accurate and consistent with MHRA approval</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigator’s Brochure in place</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Signed Manufacturer’s Authorisation in place</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shipping records verified</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Novel approaches to the diagnostic and prognostic assessment of coronary heart disease**

---

**Sponsor's Authorisation to Open Trial Site**

| Adequate resources in place to begin recruitment | ✔ | ❌ |

**Authorised Documents**

<table>
<thead>
<tr>
<th>Document</th>
<th>Current</th>
<th>Version</th>
<th>Author date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol</td>
<td>Yes</td>
<td>2.1</td>
<td>01-Dec-14</td>
</tr>
<tr>
<td>PISC</td>
<td>Yes</td>
<td>2.2</td>
<td>19-Dec-14</td>
</tr>
<tr>
<td>Pt Invite letter</td>
<td>Yes</td>
<td>1.1</td>
<td>29-Aug-14</td>
</tr>
<tr>
<td>GP letter</td>
<td>Yes</td>
<td>1.1</td>
<td>05-May-14</td>
</tr>
<tr>
<td>Pt emergency card</td>
<td>Yes</td>
<td>1.1</td>
<td>05-Jun-14</td>
</tr>
<tr>
<td>label</td>
<td>Yes</td>
<td>v0.3</td>
<td>20-Jun-14</td>
</tr>
<tr>
<td>SmPC AZ Brilique</td>
<td>Yes</td>
<td>N/A</td>
<td>24-Jul-14</td>
</tr>
<tr>
<td>90mg</td>
<td>yes</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>ARSAC</td>
<td>yes</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>label</td>
<td>yes</td>
<td>1</td>
<td>05-Feb-15</td>
</tr>
</tbody>
</table>

Confirmed as correct by trial manager on 20150302

**Declaration**

This document confers authorisation from the study sponsor to open the specified trial site for recruitment. This authorisation permits the research team to proceed with all study activities at the trial site.

---

**Signatures**

**Authorisation Completion**

Sponsor authorisation confirmed by: Javier Rojas
Job Function: Clinical Research Monitor
Signature: [Signature]
Date: 18/03/2015

**Authorisation Review**

Not Required (authorised by SCTR) [✔]

Authorisation reviewed by: not required as confirmed by Louisa Wilson 12Mar2015
Job Function:
Signature: [Signature]
Date: Click here to enter a date.
An audit was performed by a representative of the “Dual antiplatelet therapy to Inhibit coronary Atherosclerosis and Myocardial injury in patients with Necrotic high-risk coronary plaque Disease” sponsor(s) on 06 March 2015 at Edinburgh QMRI under the supervision of Edwin Carter (Responsible Scientist).

EudraCT number 2014-000952-26

The purpose of the audit was to assess the compliance of the trial in question with the requirements of the EMA laboratory sample analysis guidelines. The scope of the audit included inspection of equipment and facilities (including maintenance and other records) used for storage, preparation and analysis of study samples for the DIAMOND study. The scope also included the review of training records for individuals involved with the storage, preparation and analysis of study samples.

Any corrective/preventive actions, in response to relevant audit findings, have been initiated. The audit has been concluded.

Auditor and Accord QA Officer

Date

QA002-T06v2.0